Symptoms experienced during the first four months of chemotherapy administration: A longitudinal cohort study in an Australian cancer treatment unit

Symptoms experienced during the first four months of chemotherapy administration: A longitudinal cohort study in an Australian cancer treatment unit | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Symptoms experienced during the first four months of chemotherapy administration: A longitudinal cohort study in an Australian cancer treatment unit Kimberly E Alexander, Theodora Ogle, Brighid Scanlon, Morgan J Farley, and 11 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7993209/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 7 You are reading this latest preprint version Abstract Purpose Individuals undergoing chemotherapy experience a range of symptoms that can significantly impact their quality of life and treatment outcomes; the prevalence and severity of which can change across their treatment journey. This study aimed to identify and describe the longitudinal symptom experience during the first four months of chemotherapy administration across a range of cancer diagnoses. Methods A prospective longitudinal cohort study was conducted at a cancer centre in Queensland, Australia. Monthly surveys assessed symptoms, distress, and quality of life across four months of chemotherapy. Results A total of 252 participants completed baseline surveys (mean age 61 ± 12.3 years; 65% female; 40% breast cancer). Participants reported a mean of 22.5 ± 9.0 symptoms at baseline, with a statistically significant reduction in symptoms throughout the study period 21.9 ± 9.2 symptoms (p = 0.002). Fatigue (93%), insomnia (80%), and pain (72%) were most common at baseline and remained highly prevalent throughout the time period. Severe fatigue (25%), pain (15%), and constipation (15%) reduced over time, while peripheral neuropathy and decreased sexual interest increased. Conclusion This study has produced insights into the high number of symptoms experienced during the initial four months of chemotherapy. Given the impact of symptoms on treatment outcomes, there is a critical need for the development of appropriate assessment tools capable of capturing this broad range of patient symptom experiences. Implications for Cancer Survivors: Understanding symptom patterns over time can support early identification of high-risk patients, guide personalised supportive care strategies and optimise treatment tolerance and quality of life during and beyond chemotherapy. Oncology Symptom management Chemotherapy Cancer Care Figures Figure 1 Figure 2 Introduction Over the past decade, cancer therapies have developed significantly, resulting in improved treatment outcomes and extended survival [ 1 ]. Whilst these breakthroughs have given hope to many, patients undergoing chemotherapy continue to experience a high frequency of treatment-related symptoms, impacting their health status, quality of life (QoL), and outcomes [ 2 ]. The severity of these symptoms varies considerably between patients and throughout their treatment journey [ 3 ]. Symptoms frequently reported during chemotherapy include physical issues such as pain, fatigue, nausea, and vomiting, alongside psychological concerns such as depression and anxiety [ 4 ]. Consequently, patients undergoing chemotherapy experience frequent and variable supportive care needs. Managing the physical and psychosocial consequences of systemic anti-cancer therapies is consistently highlighted as an unmet need during survivorship. These unmet needs are associated with reduced QoL, highlighting the need for comprehensive assessment and management of the symptom experience both during and following receipt of cancer therapies [ 5 ]. Research on symptom experience and its impact on QoL is growing, but most evidence comes from cross-sectional studies measuring symptoms at a single time point [ 6 ]. This approach limits insight into symptom trajectories and overlooks the dynamic nature of treatment-related symptoms and evolving supportive care needs [ 7 ]. Longitudinal evaluation is essential to track symptom changes during treatment and guide assessment tools, interventions, and services that address patients’ unmet needs [ 7 ]. Current symptom assessment tools usually assess fewer than 20 symptoms, often underestimating or omitting significant treatment-related issues and leading to unmet supportive care needs. Studies addressing longitudinal symptom prevalence are often in population subsets, such as those undergoing treatment for breast cancer [ 8 ]. There is currently limited longitudinal evidence describing the common symptom patterns experienced during chemotherapy administration within a conventional cancer treatment centre. This lack of evidence means that current assessment tools may not adequately reflect the diversity of and changing nature of patient symptom experiences and supportive care needs. Therefore, the aim of this research was to describe the common longitudinal symptom experience in a mixed cohort of patients undergoing chemotherapy in an Australian cancer treatment unit. Methods Study design and participants A prospective, longitudinal, observational cohort study design was used to identify and describe the changes in symptom experiences, levels of distress, and QoL during the first four months of chemotherapy administration. Participants were recruited between December 2017 and January 2020 and comprised adults undergoing chemotherapy at one cancer treatment unit in metropolitan Queensland, Australia. Participants were eligible for inclusion if they met the following criteria: aged 18 years or older; were initiating chemotherapy with curative intent at the hospital and were competent to give informed consent. This study was performed in line with the principles of the Declaration of Helsinki. Ethical approval for this study was sought and obtained by the St Vincent’s Health Australia and Aged Care Committee Human Research Ethics Committee (Approval number 16/31, TARGET: Individually tailored health care program for cancer patients). Procedure Participant eligibility was established prior to recruitment through screening the oncology admission records. Eligible participants received a letter inviting them to participate in the study, as well as a consent form and information materials. Patients were enrolled in the study if they completed the associated consent form and returned it to the research team. Following enrolment, baseline questionnaires were intended to be completed as soon as possible after commencement of their first cycle of treatment and monthly electronic symptom questionnaires for three consecutive months thereafter. Up to two reminder prompts were sent via email and text message to complete the questionnaire. Follow-up phone calls were also made by the research team if a survey was not completed within three days of being administered. These calls checked whether the participant had received the email, and if the study team could assist with its completion. Three attempts at different times of the day were made to contact the participant. Data sources and variables Demographic, clinical information, health and lifestyle information Sociodemographic variables were collected at baseline, including age, sex, marital status, education, income ($AUD), family/care responsibilities, ethnicity, living arrangements, and employment. A range of clinical characteristics including cancer type and time since diagnosis were also collected at baseline from patient medical records. Self-reported health and lifestyle information was collected at baseline including height (cm) and weight (kg), smoking status, usual alcohol consumption, engagement in exercise (frequency, intensity), and use of pain medications including both over the counter and prescription products. Presence of comorbid conditions were measured using the Self-administered Comorbidity Questionnaire (SCQ) [9]. The SCQ contains 36 items about occurrence, treatment and functional impact of 12 common comorbid conditions, including cancer [10]. The Malnutrition Screening Tool (MST) was also used at baseline. The MST is a validated brief measure used to assess the risk of malnutrition [11]. The MST asks three questions including whether a person has lost weight without trying and if yes; how much, and whether they have been eating poorly due to decreased appetite [11]. Symptoms Experience Symptom experience was measured using the National Cancer Institute Patient Reported Outcome Common Terminology Criteria for Adverse Event (PRO-CTCAE). The PRO-CTCAE is validated for reporting treatment side effects in cancer clinical trials [12]. This tool is based on the CTCAE which is commonly used by clinicians to document adverse effects in cancer treatment [13]. Participants self-reported the frequency and severity of adverse events and interference with daily activities in the previous seven days, scoring items on a five-point Likert scale (ranging from 0-4) [12-14]. The PRO-CTCAE was administered at baseline and then monthly for three months thereafter. This was based on the results of a pilot study previously published by the research team [15], which determined that completion of an assessment tool on a weekly basis was too burdensome. Studies indicate that a monthly recall period is not inferior to daily reporting for data reliability [16]. PRO-CTCAE results were interpreted as per the previously published grading algorithm [17]. Quality of Life Quality of life was assessed using the Assessment of Quality of Life (AQoL-4D) which measures four dimensions of QoL including independent living, relationships, mental health and senses [18]. Participants self-reported 12 items (three items under each sub-scale) using a four-point scale (ranging from 1-4). The AQoL was developed using hospital in-patients with general medical conditions and community members and has demonstrated validity and reliability [19, 20]. Australian norms are available, derived from the Australian national survey of mental health and wellbeing. [21]. Distress Distress was measured at baseline and follow-up using the Distress Thermometer (DT), which is a brief screening tool that assesses distress levels participants have experienced in the past week. Participants scored a single item on an 11-point scale (ranging from no distress to extreme distress). The DT is sensitive to participants who do not meet anxiety or depression diagnoses [22], and has been validated for use with cancer patients [23]. Data analysis Variable transformation Scores on the PRO-CTCAE were transformed using the composite grading algorithm for PRO-CTCAE established by Basch and colleagues [24], which has been assessed for validity, reliability, and sensitivity. The grading algorithm produces a single numerical grading score for adverse events, derived from multiple PRO-CTCAE items. The grading algorithm is scored from 0-3 representing none, mild, moderate and severe symptom experience [24]. Scores on the grading algorithm were further collapsed to a binary variable (yes/no), representing those who did or did not experience adverse events. Participant height (cm) and weight (kg) information was used to generate a Body Mass Index (BMI) score (kg/m 2 ). Regarding comorbidities, scores for responses on whether participants had any of the twelve comorbidities listed on the SCQ (excluding cancer), received treatment for them and whether they limited daily activities were tallied to produce an overall SCQ score from 0-36 [10]. Individual scores on the MST questions were combined to create an overall MST score, which categorised participants as low, moderate, or high risk of malnutrition [11]. Presentation of data Descriptive statistics were used to summarise data. Chi-square was used to explore group differences on categorical variables, or Fisher’s exact test if expected cell sizes were less than five. Group differences on continuous variables were explored using t-tests, or Mann-Whitney U test if the data were not normally distributed. Repeated measures ANOVA was also undertaken and the Huynh-Feldt correction factor was applied to account for the violation of sphericity, in which observations from the same participant are likely to be correlated [25]. PRO-CTCAE scores based on the composite grading algorithm were ranked at all timepoints according to the prevalence of the top 20 symptoms experienced. A ranking of one indicated the highest symptom prevalence. This enabled symptoms to be reported as percentage change in prevalence between time points 1 and 4. Similarly, the prevalence of Grade 3 (severe) symptom severity and the percentage change in the prevalence of Grade 3 symptom severity from time 1 to 4 were reported. Missing data were not included in analyses or descriptive summaries. All data analyses were undertaken using SPSS Version 29 [26] and statistical significance was determined at a level of p<0.05. Results Participants Of the 312 eligible patients invited to participate between December 2017 and January 2020, 252 (81%) completed the baseline survey. Reasons for declining to participate included being too sick (n=17), too overwhelmed (n=7), no reason specified (n=31), or other (n=4). Most participants were female (n=164, 65%), of British decent (n=186, 76%), with a mean age of 61±12 years. Participant demographics are presented in Table 1 . Approximately 40% of participants had a diagnosis of breast cancer (n=101), 10% had bowel cancer (n=25) and 11% had lung cancer (n=28). Most had been diagnosed within the past year (n=187, 89%), with a mean age at diagnosis of 61±12 years. More than half of participants had a family history of cancer (n=142, 57%). More than three-quarters of participants were married or partnered (n=192, 77%) and just under half were employed (n=91, 36.7%). Almost half had an annual household income over $70,000 (AUD) (n=118, 47%). Table 1: Participant demographics and clinical characteristics (n=252) Demographic N (%) Sex Male 88 (34.9%) Female 164 (65.1%) Age (mean, SD) 61.0±12.3 Cancer Diagnosis Breast Cancer 101 (40.2) Bowel Cancer 25 (10.0) Lung Cancer 28 (11.2) Pancreatic Cancer 19 (7.6) Oesophageal Cancer 18 (7.2) Prostate Cancer 9 (3.6) Lymphoma 10 (4.0) Ovarian Cancer 7 (2.8) Other 34 (13.5) Age at cancer diagnosis (mean, SD) 60.1±12.3 Time since cancer diagnosis – days (mean, SD) 274.0±1219.2 Time since cancer diagnosis - years 2 years 9 (4.3%) Family history of cancer Yes 142 (57.0%) No 97 (39.0%) Unknown 10 (4.0%) Marital status Never married/partnered 18 (7.2%) Married/partnered 192 (76.8%) Divorced/separated 24 (9.6%) Widowed 16 (6.4%) Living status Living with partner and/or others 216 (86.1%) Live alone 33 (13.1%) Ethnicity British/Scottish/Welsh/Irish 186 (75.9%) European 30 (12.2%) Indigenous Australian 1 (0.4%) Asian 2 (0.8%) Pacific Islander 1 (0.4%) Other 25 (10.2%) Do you have responsibilities for children at home No 194 (77.6%) Yes 56 (22.4%) Do you have responsibilities for elders at home No 244 (97.6%) Yes 6 (2.4%) Highest level of education None 1 (0.4%) Primary 4 (1.6%) Secondary 91 (36.4%) Certificate/Diploma 81 (32.4%) Bachelor/Post-graduate 73 (29.2%) Employment Employed 91 (36.7%) Self-employed 27 (10.9%) Unemployed 10 (4.0%) Retired 120 (48.4%) Hours worked if employed (mean, SD) 33.1±11.7 Hours worked if self-employed (mean, SD) 28.1±15.1 Annual household income (AUD) 100K 81 (35.2%) Health Characteristics (baseline) Height (cm) (mean, SD) 168.1±9.1 Weight (kg) (mean, SD) 78.6±20.3 Body Mass Index (BMI – kg/m 2 ) (mean, SD) 27.7±6.9 Smoking status Current 10 (4.1%) Former 114 (46.7%) Never smoked 120 (49.2%) Alcohol consumption (drinks per week) None 140 (58.3%) 1-5 56 (22.3%) 6 or more 44 (18.3%) Alcohol consumption (daily) None 67 (28.2%) 1-2 76 (31.9%) More than 2 95 (39.9%) Use of over-the-counter pain medications (measured at baseline) No 101 (40.2%) Yes 150 (59.8%) Use of strong pain medications (eg. opioids) No 199 (79.6%) Yes 51 (20.4%) Use of Complementary and Alternative Medicines (CAMs) No 69 (27.6%) Yes 181 (72.4%) Current level of exercise None 39 (15.8%) Limited 128 (51.8%) Regular 80 (32.4%) Usual exercise intensity Low 112 (91.1%) Moderate 10 (8.1%) Vigorous 1 (0.8%) Limited/low intensity exercise 43 (35.2%) Regular/low intensity exercise 68 (55.7%) Regular/moderate intensity exercise 9 (7.4%) Usual exercise frequency (times/week) 0 146 (57.9%) 1-3 times 31 (12.3%) 4 or more times 75 (29.8%) Risk of Malnutrition (MST) 1 Low 139 (66.2%) Moderate 28 (13.3%) High 43 (20.5%) SCQ score 2 at baseline (mean, SD) 5.1±2.8 Presence of comorbidities 3 Yes 168 (67.2%) No 70 (28.0%) 1 The Malnutrition Screening Tool (MST) generates a score to define whether a participant is at risk of malnutrition based on if they have lost weight, how much weight has been lost and whether they have experienced decreased appetite 2 The Self-Administered Comorbidity Questionnaire (SCQ) score is a composite measure of 12 comorbidities experienced, if treatment is received and whether the problem causes a limitation to functioning. The maximum score possible is 36. 3 Consists of the comorbidities asked in the SCQ, but with the addition of a free text question to specify any additional comorbidities, and the exclusion of cancer, given all participants have a cancer diagnosis. Clinical characteristics The mean Body Mass Index (BMI) of the sample was in the “overweight” category (27.7±6.9). Just under half had never smoked (n=120, 49%) and 58% (n=140) did not consume alcohol on a weekly basis. Almost one-third of participants engaged in regular exercise (n=80, 32%, > four times per week) Approximately one in three (n=71, 24%) were at risk of malnutrition based on their MST score and three-quarters (n=168, 67%) had additional comorbidities. Mean SCQ score was 5.1 (±2.7) out of a possible score of 36 (with higher scores indicating increased comorbid burden). Symptom Prevalence The questionnaires assessed 54 different symptoms. At baseline, the average number of symptoms experienced by participants was 22.5±9.0 and the most prevalent symptoms were fatigue (93%), insomnia (80%), pain (72%), sadness (70%), and problems tasting food or drink (68%). Throughout the study, the number of symptoms experienced reduced to 21.9±9.2 (p=0.002). At the fourth time point, the most prevalent symptoms were fatigue (84%), pain (63%), insomnia (63%), problems tasting food or drink (59%), and aching muscles (59%). Top three symptoms overall Of the 54 symptoms assessed, fatigue, pain, and insomnia remained the top three prevalent symptoms present at both baseline and time point 4, affecting 84%, 63% and 63% of participants respectively at the final time point. Of note, there was a significant reduction in the proportions of patients that experienced fatigue (93% to 84%, p=0.005) and insomnia (80% to 63%, p = <.001), although the proportion of people with these symptoms remained high. The prevalence of pain also reduced from 72% to 63%, but this was not statistically significant (p=0.059) (see Table 2). Table 2: Ranking of symptom experience & change in prevalence from Survey 1 to Survey 4. Asterix denote significant difference at * p<0.05, ** p<0.01 and *** p<0.001 Symptom Survey 1 n = 252 Survey 4 n = 216 Change from Survey 1 to Survey 4 Rank Prevalence (overall) Prevalence (Grade 3) Rank Prevalence (overall) Prevalence (Grade 3) Relative change in prevalence (overall) Absolute change in prevalence (overall) P value a Relative change in prevalence (Grade 3) Absolute change in prevalence (Grade 3) P value c Fatigue 1 234 (92.9) 62 (24.6) 1 182 (84.3) 35 (16.2) ↓ 9.3% ↓ 8.6% 0.005** ↓ 34.2% ↓ 8.4% .030* Insomnia 2 202 (80.2) 35 (13.9) 3 135 (62.5) 21 (9.7) ↓ 22.1% ↓ 17.7% <.001** ↓ 30.2% ↓ 4.2% 0.199 Pain 3 181 (71.8) 38 (15.1) 2 137 (63.4) 20 (9.3) ↓ 11.7% ↓ 8.4% 0.059 ↓ 38.4% ↓ 5.8% 0.067 Sadness 4 177 (70.2) 17 (6.7) 7 117 (54.2) 10 (4.6) ↓22.8% ↓16.0% <.001** ↓31.3% ↓2.1% 0.427 Problems tasting food or drink 5 172 (68.3) 33 (13.1) 4 128 (59.3) 21 (9.7) ↓13.2% ↓9.0% 0.053 ↓26.0% ↓3.4% 0.310 Headache 6 166 (65.9) 3 (1.2) 18 97 (44.9) 2 (0.9) ↓31.9% ↓21.0% <0.001** ↓25.0% ↓0.3% 1.000 Constipation 7 165 (65.5) 37 (14.7) 17 99 (45.8) 11 (5.1) ↓30.1% ↓19.7% <.001** ↓65.3% ↓9.6% <.001** Diarrhea 8 159 (63.1) 6 (2.4) 7 117 (54.2) 4 (1.9) ↓14.1% ↓8.9% 0.059 ↓20.8% ↓0.5% 0.759 Anxiety 9 158 (62.7) 18 (7.1) 6 119 (55.1) 3 (1.4) ↓12.1% ↓7.6% 0.109 ↓80.9% ↓5.7% 0.003** Hair loss b 10 150 (59.5) NA 13 107 (49.5) NA 0.032* NA Decreased appetite 10 150 (59.5) 35 (13.9) 12 109 (50.5) 16 (7.4) ↓15.1% ↓9.0% 0.051 ↓46.8% ↓6.5% 0.026* Dry mouth 10 150 (59.5) 18 (7.1) 18 97 (44.9) 15 (6.9) ↓24.5% ↓14.6% 0.002** ↓2.8% ↓0.2% 1.000 Nausea 12 146 (57.9) 27 (10.7) 19 95 (44.0) 6 (2.8) ↓24.0% ↓13.9% 0.003** ↓73.8% ↓7.9% <.001** Bloating 12 146 (57.9) 15 (6.0) 11 111 (51.4) 10 (4.6) ↓11.2% ↓6.5% 0.163 ↓23.3% ↓1.4% 0.545 Frequent urination 13 145 (57.5) 0 16 100 (46.3) 0 0.016* NA Abdominal pain 14 144 (57.1) 22 (8.7) 11 111 (51.4) 8 (3.7) ↓10.0% ↓5.7% 0.227 ↓57.5% ↓5.0% 0.036* Concentration 14 144 (57.1) 14 (5.6) 8 115 (53.2) 8 (3.7) ↓6.8% ↓3.9% 0.403 ↓33.9% ↓1.9% 0.388 Aching muscles 15 140 (55.6) 18 (7.1) 5 127 (58.8) 9 (4.2) ↑5.8% ↑3.2% 0.513 ↓40.1% ↓2.9% 0.232 Sudden urge to urinate 16 136 (54.0) 0 20 93 (43.1) 0 0.021* NA Dry skin 17 134 (53.2) 11 (4.4) 10 113 (52.3) 7 (3.2) ↓1.7% ↓0.9% 0.853 ↓27.3% ↓1.2% 0.633 Memory 18 130 (51.6) 9 (3.6) 9 114 (52.8) 5 (2.3) ↑2.3% ↑1.2% 0.853 ↓36.1% ↓1.3% 0.588 Heartburn 19 129 (51.2) 17 (6.7) 21 88 (40.7) 7 (3.2) ↓20.5% ↓10.5% 0.026* ↓52.2% ↓3.5% 0.096 Shortness of breath 20 125 (49.6) 16 (6.3) 14 105 (48.6) 11 (5.1) ↓2.0% ↓1.0% 0.853 ↓19.1% ↓1.2% 0.692 Aching joints 21 118 (46.8) 13 (5.2) 15 103 (47.7) 9 (4.2) ↑1.9% ↑0.9% 0.853 ↓19.2% ↓1.0% 0.667 Dizziness 22 103 (40.9) 13 (5.2) 25 75 (34.7) 5 (2.3) ↓15.2% ↓6.2% 0.182 ↓55.8% ↓2.9% 0.148 Decreased sexual interest 23 96 (38.1) 22 (8.7) 31 59 (27.3) 21 (9.7) ↓28.4% ↓10.8% 0.014* ↑11.5% ↑1.0% 0.750 Neuropathy 23 96 (38.1) 10 (4.0) 4 128 (59.3) 22 (10.2) ↑55.6% ↑21.2% <0.001** ↑155.0% ↑6.2% 0.010* Mouth or throat sores 24 95 (37.7) 11 (4.4) 34 52 (24.1) 5 (2.3) ↓36.1% ↓13.6% 0.002** ↓47.7% ↓2.1% 0.309 Blurry vision 25 92 (36.5) 5 (2.0) 22 86 (39.8) 5 (2.3) ↑17.8 ↑6.5% 0.504 ↑25.0% ↑0.03% 1.000 Itchy skin 26 91 (36.1) 5 (2.0) 23 85 (39.4) 3 (1.4) ↑9.1% ↑3.3% 0.503 ↓30.0% ↓0.6% 0.731 Cough 26 91 (36.1) 7 (2.8) 27 69 (31.9) 4 (1.9) ↓11.3% ↓4.2% 0.379 ↓32.1% ↓0.9% 0.557 Depression 27 88 (34.9) 12 (4.8) 29 65 (30.1) 7 (3.2) ↓13.8% ↓4.8% 0.278 ↓33.3% ↓1.6% 0.485 Difficulty swallowing 28 83 (32.9) 11 (4.4) 32 57 (26.4) 5 (2.3) ↓19.8% ↓6.5% 0.130 ↓47.7% ↓2.1% 0.309 Unexpected or excessive sweating 29 82 (32.5) 8 (3.2) 28 68 (31.5) 8 (3.7) ↓3.1% ↓1.0% 0.843 ↑15.6% ↑0.5% 0.803 Hot flashes 30 77 (30.6) 9 (3.6) 26 70 (32.4) 6 (2.8) ↑5.9% ↑1.8% 0.690 ↓22.2% ↓0.8% 0.794 Watery eyes 31 75 (29.8) 7 (2.8) 24 80 (37.0) 7 (3.2) ↑24.2% ↑7.2% 0.115 ↑14.3% ↑0.4% 0.792 Palpitations 32 74 (29.4) 5 (2.0) 36 48 (22.2) 4 (1.9) ↓24.5% ↓7.2% 0.091 ↓5.0% ↓0.1% 1.000 Hoarse voice 33 68 (27.0) 5 (2.0) 34 52 (24.1) 4 (1.9) ↓10.7% ↓2.9% 0.524 ↓5.0% ↓0.1% 1.000 Tinnitus 34 65 (25.8) 6 (2.4) 33 54 (25.0) 5 (2.3) ↓3.1% ↓0.8% 0.915 ↓4.2% ↓0.1% 1.000 Shivering or shaking chills 35 62 (24.6) 6 (2.4) 39 44 (20.4) 5 (2.3) ↓17.1% ↓4.2% 0.319 ↓4.2% ↓0.1% 1.000 Body odour 36 62 (24.6) 2 (0.8) 42 35 (16.2) 0 ↓34.2% ↓8.4% 0.030* ↓100% ↓0.8% 0.502 Loss of control of bowel movements 37 61 (24.2) 0 40 43 (19.9) 0 ↓17.8% ↓4.3% 0.316 NA Hiccups 38 58 (23.0) 4 (1.6) 43 33 (15.3) 1 (0.5) ↓33.5% ↓7.7% 0.036* ↓68.8% ↓1.1% 0.380 Acne 38 58 (23.0) 1 (0.4) 37 46 (21.3) 5 (2.3) ↓7.4% ↓1.7% 0.738 ↑475% ↑1.9% 0.100 Loss of control of urine 38 58 (23.0) 0 29 65 (30.1) 0 ↑30.9% ↑7.1% 0.092 0% 0% NA Swelling 39 51 (20.2) 2 (0.8) 30 64 (29.6) 5 (2.3) ↑46.5% ↑9.4% 0.024* ↑187.5% ↑1.5% 0.257 Breast enlargement or tenderness 40 45 (17.9) 2 (0.8) 41 41 (19.0) 0 ↑6.2% ↑1.1% 0.811 ↓100% ↓0.8% 0.502 Cheilitis 41 44 (17.5) 5 (2.0) 38 45 (20.8) 1 (0.5) ↑18.9 ↑3.3% 0.408 ↓75.0% ↓1.5% 0.224 Wheezing 42 41 (16.3) 1 (0.4) 47 25 (11.6) 1 (0.5) ↓28.8% ↓4.7% 0.183 ↑25% ↑0.1% 1.000 Vomiting 43 39 (15.5) 2 (0.8) 46 28 (13.0) 2 (0.9) ↓16.1% ↓2.5% 0.508 ↑12.5% ↑0.1% 1.000 Nosebleed 43 35 (13.9) 0 35 51 (23.6) 2 (0.9) ↑69.8% ↑9.7% 0.008** ↑200% ↑0.9% 0.212 Dysuria 44 29 (11.5) 5 (2.0) 44 30 (13.9) 3 (1.4) ↑20.9% ↑2.4% 0.486 ↓30.0% ↓0.6% 0.731 Hand and foot syndrome 45 17 (6.7) 2 (0.8) 45 29 (13.4) 4 (1.9) ↑100% ↑6.7% 0.019* ↑137.5% ↑1.1% 0.421 Skin burns from radiation 46 7 (2.8) 1 (0.4) 48 15 (6.9) 1 (0.5) ↓62.3% ↓11.4% 0.047* ↑25% ↑0.1% 1.000 Notes: PRO-CTCAE scores based on the composite grading algorithm were ranked at Survey 1 and Survey 4 based on the prevalence of symptom experience. A ranking of one indicated the highest symptom prevalence. Given the mean number of symptoms experienced across all timepoints was 22.7 (±9.3), we were particularly interested in the change of ranking and prevalence of the top 20 most frequently occurring symptoms and whether they remained, became or were no longer a top 20 symptom between Survey 1 and 4. Symptoms were also reported on with respect to the percentage change in prevalence of symptom experience, that is, the percentage change between percentage prevalence for symptom experience from Survey 1 to 4. Similarly, we also reported on the prevalence of Grade 3 symptom severity (i.e. severe) and the percentage change in prevalence of Grade 3 symptom severity from Survey 1 to 4. a Comparisons between Survey 1 and Survey 4 were made using c 2 tests, including Fisher’s exact test, where appropriate. b The greatest severity for hair loss is Grade 2 c P value for Grade 3 severity compared to all other categories Symptom Severity Grade 3 symptoms Whilst > 50% of patients experienced more than 20 symptoms at baseline, less than 25% experienced these at a severe (Grade 3) intensity or worse. The Grade 3 or worse intensity symptoms at baseline that affected more than 10% of patients included fatigue (25%), pain (15%), constipation (15%), insomnia (14%), decreased appetite (14%), problems tasting food and drink (14%), and nausea (11%) (See Table 2). There were significant improvements in Grade 3 intensity of fatigue, constipation, anxiety, nausea, decreased appetite, and abdominal pain, however the proportion of patients experiencing Grade 3 intensity peripheral neuropathy increased significantly by the fourth time point (p=0.010) (See Figure 1 and 2). Quality of life and Distress Overall QoL improved significantly between time points one and four (p=0.015), as well as the sub-scales of relationships (p <0.001), and senses (p =0.006). An improvement was also observed for mean distress scores which significantly improved from 3.6±2.7 at baseline to 2.7±2.7 at the last follow-up ( p < 0.001). These data are presented in Table 3. Table 3: Assessment of Quality of Life (AQoL) & Symptom Experience Survey 1 (n=252) M (SD) Mdn (IQR) Survey 2 (n=233) M (SD) Mdn (IQR) Survey 3 (n=225) M (SD) Mdn (IQR) Survey 4 (n=216) M (SD) Mdn (IQR) P value a P value b AQoL c overall .702 (± .214) .713 (.32) .670 (± .235) .705 (.33) .695 (± .219) .723 (.33) .682 (± .226) .706 (.30) .015* .028* AQoL IL subscale .859 (± .182) .876 (.22) .849 (± .197) .876 (.7) .870 (± .177) .876 (.17) .858 (± .191) .876 (.22) .359 .344 AQoL REL subscale .926 (± .110) .969 (.10) .899 (± .132) .899 (.16) .900 (± .126) .899 (.16) .897 (± .130) .899 (.16) <.001** <.001** AQoL SEN scale .949 (± .069) 1.00 (.09) .938 (± .079) .941 (.09) .941 (± .068) .941 (.09) .939 (± .071) .941 (.32) .006** .033* AQoL MH scale .887 (± .097) .893 (.10) .881 (± .109) .893 (.12) .891 (± .107) .912 (.13) .887 (± .096) .892 (.10) .564 .482 Distress Thermometer score d 3.6 (± 2.7) 3.0 (5) 2.8 (± 2.5) 2.0 (5) 2.6 (± 2.4) 2.0 (4) 2.7 (± 2.7) 2.0 (4) <.001** <.001** Number of symptoms experienced e 22.5 (± 9.0) 22.0 (13) 23.6 (±9.2) 24.0 (13.8) 22.7 (± 9.6) 24.0 (14.0) 21.9 (± 9.2) 22.0 (13.0) .223 0.002** Abbreviations: AQoL – Assessment of Quality of Life; IL – Independent Living; REL – Relationships; SEN – Sensory; MH – Mental Health; M – Mean; Mdn – Median; SD – Standard Deviation; IQR – Interquartile Range Notes: a Comparisons between Survey 1 and Survey 4 were conducted using paired samples test, with * p<0.05, ** p<0.01, *** p<0.001 b Comparisons across Surveys 1 to 4 were conducted using ANOVA repeated measures applying Huynh-Feldt correction factor, with * p<0.05, ** p<0.01, *** p<0.001 c The Assessment of Quality of Life (AQoL) measure consists of an overall score with minimum and maximum possible scores of 12 and 48 respectively. Lower scores represent better quality of life than higher scores. The tool contains four subscales to measure the domains of Independent Living (IL), Relationships (REL), Sensory (SEN), and Mental Health (MH). Each subscale has a minimum and maximum possible score of zero and 12 respectively. Utility scoring has been applied as per http://www.aqol.com.au/index.php/norms d The Distress Thermometer score measures how much distress is experienced over a seven-day period. The minimum and maximum possible scores are zero and ten respectively. e The total number of symptoms experienced, regardless of level of severity or frequency and not including sex-specific variables. The maximum possible number of symptoms experienced is 54. Discussion This prospective, longitudinal cohort study demonstrates the critical need to understand the dynamic and changing symptoms experienced during treatment. The longitudinal data provides novel insights into symptoms experienced during the first four months of chemotherapy, many of which are seldom assessed in current assessment tools [ 6 , 27 ]. To our knowledge, this is the first study that reports on the PRO-CTCAE outcomes using the composite grading algorithm in a non-clinical trial setting. Findings revealed a substantial symptom burden, with a mean prevalence of 22.5 of the 54 screened symptoms. The most common symptoms during the first four months of chemotherapy were fatigue, insomnia, pain, sadness, and taste problems. Although the overall symptom burden decreased, the average number of symptoms remained high at 21.9 by the fourth timepoint. This is an important because current instruments often report a narrow set of symptoms [ 6 , 27 ]. Conversely, more comprehensive assessment tools often evaluate multiple dimensions experienced in individual symptoms or tumour streams [ 27 , 28 ]. This demonstrates that current tools may underestimate or omit important symptoms, leading to incomplete clinical pictures, suboptimal patient care, and reduced patient outcomes [ 29 ]. Findings demonstrated that overall QoL and distress scores significantly improved between timepoints one and four. This improvement in QoL and distress scores persisted despite the relatively high burden of symptoms experienced across the study period. The clinical relevance of the improvement in distress thermometer scores is unclear, as the mean scores at all time points were below the clinically actionable level of 4 [ 30 ], however there was a statistically significant reduction from timepoint one to timepoint four. These improvements over time are supported by the wider literature which suggests that with effective supportive care interventions it is possible for QoL and distress to improve despite the presence of symptoms [ 31 , 32 ]. Further studies should explore the role of comprehensive supportive care and symptom management to address QoL and distress during chemotherapy administration. Consistent with previous research, we identified the persistence of fatigue, pain, and insomnia as the three most frequently reported symptoms throughout the first four-months of chemotherapy administration [ 33 , 34 ]. Despite a statistically significant reduction in their prevalence over the timepoints, these symptoms remained highly prevalent and were among the four most common Grade 3 (severe) symptoms experienced, alongside constipation. These findings demonstrate the chronic nature of fatigue, pain, and insomnia during chemotherapy, as well as the tendency of these symptoms to manifest at severe levels and impacting QoL [ 35 ]. Importantly, certain populations may be at higher risk of developing symptoms, such as elevated fatigue in postmenopausal women and those undergoing hormonal changes [ 36 ]. Pain has been shown to be experienced at higher rates amongst those experiencing psychological distress [ 37 ]. This highlights the need for a comprehensive, patient-centred approach to symptom management, which integrates both physical and psychological symptoms and their impacts to patient QoL [ 29 ]. Furthermore, early assessment of these symptoms could enable early supportive care interventions [ 38 ]. Most symptoms reduced over the study, however, chemotherapy-induced peripheral neuropathy (CIPN) worsened, with a 55.6% relative increase in prevalence (21.2% absolute change) by the fourth timepoint. This is concerning due to the long-term health effects associated CIPN such as ongoing pain, sensory loss, reduced dexterity, and gait disturbances [ 39 ]. These effects predispose patients to higher risk of injury and falls as well as worsening QoL and daily functioning [ 39 , 40 ]. There are currently limited treatment options for CIPN, suggesting a critical need for the early integration of supportive care strategies to optimise function and QoL [ 39 ]. Importantly, we identified a high symptom burden of non-specific symptoms such as aching muscles, reduced concentration, hiccups, and dry mouth. Literature indicates that vague, non-life-threatening symptoms are often deprioritised in clinical care despite significantly impacting QoL [ 41 – 44 ]. During treatment, clinicians often prioritise monitoring and managing potentially life-threatening side effects or those that could necessitate treatment discontinuation. Despite inadequate assessment of these symptoms, many can be improved with relatively simple lifestyle or supportive care strategies, such as regular exercise [ 44 ]. Collectively, this suggests a need for comprehensive assessment to identify and respond to non-specific symptoms. There are several limitations to consider in interpreting the results of this study. Firstly, participants included in this study were all undergoing chemotherapy at one private hospital. While a diverse range of cancer diagnoses and treatments were included, some symptoms may have been a manifestation of their diagnosis not their treatment. Secondly, people attending a private cancer center are typically of higher socio-economic status, suggesting that they may have greater access to supportive care services and social support [ 45 ]. Therefore, these results may not be reflective of the symptom experience of populations attending a public cancer service. As the purpose of this study was to represent the needs of a typical population of patients presenting for cancer treatment at a metropolitan hospital, the diversity of the sample included in this study enables a description of the types of needs and experiences that are common in a standard treatment setting on a day-to-day basis. Moreover, the data reported in this study are reflective of only the first four months of receiving systemic cancer treatment. While this longitudinal study is novel in terms of its follow-up of patients over a four-month period, the conclusions drawn are limited to this time period. Continued symptom monitoring for the time following treatment completion may shed further light on the time course of symptom experiences and how best to care for patients following completion of first line treatment. Further, we have not made any adjustment for the number of chemotherapy sessions a patient has had, nor the type of chemotherapy, as this may influence the type and severity of presenting symptoms (for example, the well-established relationship between peripheral neuropathy and platinum- or taxane-based chemotherapy [ 46 ]). Such factors are critical to explaining why some patients are more likely to experience higher levels of symptoms than others and provide further data that is needed to inform targeted interventions. [ 46 ]). Conclusion This novel research has produced valuable longitudinal insights into the common and most burdensome symptoms experienced by patients attending a metropolitan cancer setting during the first four months of chemotherapy administration. Collectively these findings highlight the need for more robust assessment tools that are utilised early in patients’ treatment journey and used to inform referral management of treatment-related side effects. While there may be barriers to implementation of routine patient reported measures into routine oncology care, the findings of this study provide evidence which supports the benefits of comprehensive assessment of patients to ensure optimal patient outcomes are achieved [ 47 ].[ 47 ] The findings of this study suggest that addressing a broader spectrum of patient-reported symptoms during cancer treatment, including those often overlooked, can provide important data to enhance quality of care and improve patient outcomes. Implications for Practice These findings underscore the importance of implementing robust assessment tools early in the patient care pathway to guide referral and management of treatment-related side effects. There is a clear need to expand symptom assessment beyond current assessment tools to enable tailored, comprehensive symptom management and optimise patient outcomes. Declarations Author Contributions: Study conceptualisation, data curation, formal analysis, funding acquisition, investigation and methodology KA, PY, SL, MC, RA, LD, EH, HH, EP, NB, MB, PI. Formal analysis, data visualisation, writing (original draft) KA, TO, BS, MF. All authors reviewed the final manuscript. Funding : This work was supported through Queensland University of Technology and St Vincent’s Private Hospital Northside. Disclosures and Acknowledgements: The authors have no relevant financial or non-financial interests to disclose. The research team would like to acknowledge the contributions of Ms Jennifer Barralet in the establishment of this project. We would also like to acknowledge the support of Queensland University of Technology, Faculty of Health, St Vincent’s Private Hospital Northside, and all hospital staff and patients who supported this project. Data Availability The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. References Cancer . 2024 [cited 2025; Available from: https://www.aihw.gov.au/reports/australias-health/cancer. Monnery, D., et al., Multi-professional-delivered enhanced supportive care improves quality of life for patients with incurable cancer. Int J Palliat Nurs, 2018. 24 (10): p. 510-514. Basch, E., et al., Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA, 2017. 318 (2): p. 197-198. Perez-Alfonso, K.E. and V. Sanchez-Martinez, Electronic Patient-Reported Outcome Measures Evaluating Cancer Symptoms: A Systematic Review. Semin Oncol Nurs, 2021. 37 (2): p. 151145. Hsu, M.L., et al., Unmet Needs, Quality of Life, and Financial Toxicity Among Survivors of Lung Cancer. JAMA Netw Open, 2024. 7 (4): p. e246872. Esther Kim, J.E., et al., A review of the prevalence and impact of multiple symptoms in oncology patients. J Pain Symptom Manage, 2009. 37 (4): p. 715-36. Thomas, B.C., et al., A longitudinal analysis of symptom clusters in cancer patients and their sociodemographic predictors. J Pain Symptom Manage, 2014. 47 (3): p. 566-78. Ho, S.Y., et al., A longitudinal study of depression, fatigue, and sleep disturbances as a symptom cluster in women with breast cancer. J Pain Symptom Manage, 2015. 49 (4): p. 707-15. Sangha, O., et al., The self-administered comorbidity questionnaire: A new method to assess comorbidity for clinical and health services research. Arthritis Care and Research, 2003. 49 (2): p. 156-163. Sangha, O., et al., The self‐administered comorbidity questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Care & Research, 2003. 49 (2): p. 156-163. Ferguson, M., et al., Development of a valid and reliable malnutrition screening tool for adult acute hospital patients. Nutrition (Burbank, Los Angeles County, Calif.), 1999. 15 (6): p. 458-464. National Cancer Institute. Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) . 2016 [cited 2016 10 October]; Available from: https://healthcaredelivery.cancer.gov/pro-ctcae/. Basch, E., et al., Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Journal of the National Cancer Institute, 2014. 106 (9): p. 1-11. Kluetz, P.G., et al., Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). American Society of Clinical Oncology educational book, 2016. 35 : p. 67-73. Phung, T.H., et al., Unleashing patient voices: empowering adverse event assessment with complete patient-reported outcomes. Oncologist, 2024. 29 (7): p. e953-e956. Mendoza, T.R., et al., Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE. Clin Trials, 2017. 14 (3): p. 255-263. Basch, E., et al., Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Clin Trials, 2021. 18 (1): p. 104-114. Assessment of Quality of Life . 2016 [cited 2016 31 October]; Available from: http://www.aqol.com.au/index.php/aqolinstruments. Hawthorne, G., J. Richardson, and N.A. Day, A comparison of the Assessment of Quality of Life (AQoL) with four other generic utility instruments. Annals of Medicine, 2001. 33 (5): p. 358-70. Hawthorne, G., J. Richardson, and R. Osborne, The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health-related quality of life. Quality of Life Research, 1999. 8 (3): p. 209-24. Hawthorne, G., S. Korn, and J. Richardson, Population norms for the AQoL derived from the 2007 Australian National Survey of Mental Health and Wellbeing. Australian and New Zealand Journal of Public Health, 2013. 37 (1): p. 7-16. Jacobsen, P.B., et al., Screening for psychologic distress in ambulatory cancer patients. Cancer, 2005. 103 (7): p. 1494-502. Goebel, S. and H.M. Mehdorn, Measurement of psychological distress in patients with intracranial tumours: the NCCN distress thermometer. Journal of Neuro-Oncology, 2011. 104 (1): p. 357-64. Basch, E., et al., Composite grading algorithm for the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Clinical trials (London, England), 2021. 18 (1): p. 104-114. Huynh, H. and L.S. Feldt, Estimation of the Box Correction for Degrees of Freedom from Sample Data in Randomized Block and Split-Plot Designs. Journal of Educational Statistics, 1976. 1 (1). IBM SPSS software . 2024; Available from: https://www.ibm.com/spss. Deshields, T.L., et al., The persistence of symptom burden: symptom experience and quality of life of cancer patients across one year. Support Care Cancer, 2014. 22 (4): p. 1089-96. Lavdaniti, M., Assessment of Symptoms in Cancer Patients Undergoing Chemotherapy in Northern Greece. Mater Sociomed, 2015. 27 (4): p. 255-8. Al Qadire, M., et al., Identifying Symptom Clusters in Cancer Patients Receiving Chemotherapy using Symptom Occurrence and Distress Dimensions. Clin Nurs Res, 2023. 32 (1): p. 185-196. Cutillo, A., et al., The Distress Thermometer: Cutoff Points and Clinical Use. Oncol Nurs Forum, 2017. 44 (3): p. 329-336. Nguyen, L.B., et al., Impact of interventions on the quality of life of cancer patients: a systematic review and meta-analysis of longitudinal research. Health Qual Life Outcomes, 2023. 21 (1): p. 112. Liu, X., et al., The impact of cognitive behavioral therapy on disease uncertainty, stressful life events, quality of life, anxiety, and depression in glioma patients undergoing chemotherapy: a quasi-experimental study. BMC Psychiatry, 2025. 25 (1): p. 272. Sasaki, H., et al., Patient perceptions of symptoms and concerns during cancer chemotherapy: 'affects my family' is the most important. Int J Clin Oncol, 2017. 22 (4): p. 793-800. Molassiotis, A., et al., Mapping unmet supportive care needs, quality-of-life perceptions and current symptoms in cancer survivors across the Asia-Pacific region: results from the International STEP Study. Ann Oncol, 2017. 28 (10): p. 2552-2558. Oh, P.J. and J.R. Cho, Changes in Fatigue, Psychological Distress, and Quality of Life After Chemotherapy in Women with Breast Cancer: A Prospective Study. Cancer Nurs, 2020. 43 (1): p. E54-E60. Hickey, M., et al., Managing menopause after cancer. Lancet, 2024. 403 (10430): p. 984-996. Mehndiratta, S., et al., A review based study on emotional distress and physical pain in oral and head and neck cancer patients pre- and post-chemotherapy. Oral Oncology Reports, 2024. 11 : p. 100637. Cormie, P., et al., The Impact of Exercise on Cancer Mortality, Recurrence, and Treatment-Related Adverse Effects. Epidemiol Rev, 2017. 39 (1): p. 71-92. Bao, T., et al., Health-Related Quality of Life in Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Clinical Trial. Oncologist, 2021. 26 (11): p. e2070-e2078. Tofthagen, C., J. Overcash, and K. Kip, Falls in persons with chemotherapy-induced peripheral neuropathy. Support Care Cancer, 2012. 20 (3): p. 583-9. Schlatter, M.C. and L.D. Cameron, Emotional suppression tendencies as predictors of symptoms, mood, and coping appraisals during AC chemotherapy for breast cancer treatment. Ann Behav Med, 2010. 40 (1): p. 15-29. Jensen, E., et al., The pathway and characteristics of patients with non-specific symptoms of cancer: a systematic review. BMC Cancer, 2022. 22 (1): p. 574. Lee, G.W., et al., Treatment of dexamethasone-induced hiccup in chemotherapy patients by methylprednisolone rotation. Oncologist, 2013. 18 (11): p. 1229-34. Adesoye, T., et al., Patient-reported outcomes in older breast cancer survivors with and without prior chemotherapy treatment. Cancer Med, 2023. 12 (17): p. 17740-17752. Rana, R.H., K. Alam, and J. Gow, Selection of private or public hospital care: examining the care-seeking behaviour of patients with private health insurance. BMC Health Serv Res, 2020. 20 (1): p. 380. Brown, T.J., R. Sedhom, and A. Gupta, Chemotherapy-Induced Peripheral Neuropathy. JAMA Oncol, 2019. 5 (5): p. 750. Roberts, N.A., et al., What is needed by staff to implement PROMs into routine oncology care? A qualitative study with the multi-disciplinary team. Eur J Cancer Care (Engl), 2019. 28 (6): p. e13167. Additional Declarations No competing interests reported. Supplementary Files SupplementaryTable1.docx Cite Share Download PDF Status: Under Review Version 1 posted Editorial decision: Revision requested 15 Apr, 2026 Reviews received at journal 22 Mar, 2026 Reviewers agreed at journal 02 Mar, 2026 Reviewers invited by journal 12 Dec, 2025 Editor assigned by journal 12 Dec, 2025 Submission checks completed at journal 20 Nov, 2025 First submitted to journal 30 Oct, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7993209","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":560476414,"identity":"ae2e0ed7-0b85-4ee4-995f-15057d943f3a","order_by":0,"name":"Kimberly E Alexander","email":"","orcid":"","institution":"Queensland University of Technology","correspondingAuthor":false,"prefix":"","firstName":"Kimberly","middleName":"E","lastName":"Alexander","suffix":""},{"id":560476421,"identity":"5581dc72-d487-4d20-ad3e-a057bc5b9634","order_by":1,"name":"Theodora Ogle","email":"","orcid":"","institution":"Queensland University of Technology","correspondingAuthor":false,"prefix":"","firstName":"Theodora","middleName":"","lastName":"Ogle","suffix":""},{"id":560476423,"identity":"b8f9398f-ed66-4a1e-b989-49583dd56ff9","order_by":2,"name":"Brighid Scanlon","email":"","orcid":"","institution":"Queensland University of Technology","correspondingAuthor":false,"prefix":"","firstName":"Brighid","middleName":"","lastName":"Scanlon","suffix":""},{"id":560476426,"identity":"f3914874-a497-43c1-af11-6fca8617864b","order_by":3,"name":"Morgan J Farley","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA4klEQVRIiWNgGAWjYFACxgcMDAUMDPwQHjMxWpgNGBiASLKBgbGBNC0GB4jVotvAzPi5wsAmcfPxHPMHDBXWiQ3sZwzwajE7wMwsecYgLXHbmTeGDQxn0hMbeHIIaeE/INlgcDhx240cwwbGtsOJDQwEtTAz/2ww+J+4eQZIyz+gFv43BLWwAW05kLhBAqSlAahFgpAth5nZLBsMko1nnHlWOCPhWLpxm8SzAvxajjcz32yosJPtb0/e8OFDjbVsP3/yBrxaYBHh2MCQwABCDGz41SOAPUT9KBgFo2AUjAIsAAAEJkbfJz6FLwAAAABJRU5ErkJggg==","orcid":"","institution":"Queensland University of Technology","correspondingAuthor":true,"prefix":"","firstName":"Morgan","middleName":"J","lastName":"Farley","suffix":""},{"id":560476429,"identity":"17e3c7da-9247-4f69-bef8-726e8088e2af","order_by":4,"name":"Natalie Bradford","email":"","orcid":"","institution":"Queensland University of Technology","correspondingAuthor":false,"prefix":"","firstName":"Natalie","middleName":"","lastName":"Bradford","suffix":""},{"id":560476431,"identity":"cd651bf3-dc02-4e64-8f61-91d904924101","order_by":5,"name":"Erin Pitt","email":"","orcid":"","institution":"University of Queensland","correspondingAuthor":false,"prefix":"","firstName":"Erin","middleName":"","lastName":"Pitt","suffix":""},{"id":560476432,"identity":"4824a461-d432-42b3-b6f0-f2b33820ccad","order_by":6,"name":"Hana Hoberg","email":"","orcid":"","institution":"Royal Brisbane and Women's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Hana","middleName":"","lastName":"Hoberg","suffix":""},{"id":560476433,"identity":"9efa81c4-e279-477e-9055-1e59a405d158","order_by":7,"name":"Elizabeth Herron","email":"","orcid":"","institution":"Royal Brisbane and Women's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Elizabeth","middleName":"","lastName":"Herron","suffix":""},{"id":560476434,"identity":"b5dc2e67-3b63-4f5e-996c-e6f31e0aa3a6","order_by":8,"name":"LeeAnn Doyle","email":"","orcid":"","institution":"St Vincent's Hospital","correspondingAuthor":false,"prefix":"","firstName":"LeeAnn","middleName":"","lastName":"Doyle","suffix":""},{"id":560476435,"identity":"78ea37d1-76d3-4e1a-bbfb-7f542a1b01e9","order_by":9,"name":"Rick Abraham","email":"","orcid":"","institution":"St Vincent's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Rick","middleName":"","lastName":"Abraham","suffix":""},{"id":560476436,"identity":"45c99618-84d5-4cd5-96bc-35f82fdf3fa1","order_by":10,"name":"Mark Bentley","email":"","orcid":"","institution":"Icon Cancer Centre","correspondingAuthor":false,"prefix":"","firstName":"Mark","middleName":"","lastName":"Bentley","suffix":""},{"id":560476437,"identity":"34e9b0e1-6055-40e7-8e1e-1dd5c744d9fc","order_by":11,"name":"Po-ling Inglis","email":"","orcid":"","institution":"Metro North Health","correspondingAuthor":false,"prefix":"","firstName":"Po-ling","middleName":"","lastName":"Inglis","suffix":""},{"id":560476438,"identity":"44fefea4-2fbb-4c2e-bbb1-9cce913b8d8e","order_by":12,"name":"Maree Colosimo","email":"","orcid":"","institution":"St Vincent's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Maree","middleName":"","lastName":"Colosimo","suffix":""},{"id":560476439,"identity":"d4abd5fd-3930-4499-9a2f-fa24b774c268","order_by":13,"name":"Steven Lane","email":"","orcid":"","institution":"QIMR Berghofer Medical Research Institute","correspondingAuthor":false,"prefix":"","firstName":"Steven","middleName":"","lastName":"Lane","suffix":""},{"id":560476440,"identity":"3f194eb0-2dc3-4e18-b847-653068e86b6d","order_by":14,"name":"Patsy Yates","email":"","orcid":"","institution":"Queensland University of Technology","correspondingAuthor":false,"prefix":"","firstName":"Patsy","middleName":"","lastName":"Yates","suffix":""}],"badges":[],"createdAt":"2025-10-31 01:08:11","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7993209/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7993209/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":98780070,"identity":"b6681e8b-b161-48c1-b2e6-6221d48a8d65","added_by":"auto","created_at":"2025-12-22 12:31:02","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1360586,"visible":true,"origin":"","legend":"","description":"","filename":"JCSTARGETV2tracked.docx","url":"https://assets-eu.researchsquare.com/files/rs-7993209/v1/c94f38f677bee4db1be53233.docx"},{"id":98754794,"identity":"35c5db46-dcc3-4ded-b8b3-d1d7d69128d4","added_by":"auto","created_at":"2025-12-22 09:25:14","extension":"json","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":14576,"visible":true,"origin":"","legend":"","description":"","filename":"c53685b876a4468e81e3e102eb1d6a5f.json","url":"https://assets-eu.researchsquare.com/files/rs-7993209/v1/b751c8a5c60126883f73e678.json"},{"id":98754795,"identity":"ba23ce1c-5803-4aae-8b23-68bec2115f58","added_by":"auto","created_at":"2025-12-22 09:25:14","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":23331,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryTable1.docx","url":"https://assets-eu.researchsquare.com/files/rs-7993209/v1/23436872b30a7b18803f77ce.docx"},{"id":98778893,"identity":"9ef8a220-ae15-42ab-a2e6-103ff488ce88","added_by":"auto","created_at":"2025-12-22 12:29:47","extension":"xml","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":189094,"visible":true,"origin":"","legend":"","description":"","filename":"c53685b876a4468e81e3e102eb1d6a5f1enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-7993209/v1/a1011a901c8181be1d630b45.xml"},{"id":98754807,"identity":"c04e849d-cb45-4910-8ea9-8c503ae22485","added_by":"auto","created_at":"2025-12-22 09:25:15","extension":"png","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":84575,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-7993209/v1/6f5b6ea6ce7cca1fad614a57.png"},{"id":98754798,"identity":"d6a303d2-a723-4eba-b756-5fd686d83806","added_by":"auto","created_at":"2025-12-22 09:25:14","extension":"jpeg","order_by":5,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1074,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage2.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-7993209/v1/33d97213ac06be1049c03884.jpeg"},{"id":98780091,"identity":"bd7f950c-242d-4be5-aac7-a5a2e49a0e0f","added_by":"auto","created_at":"2025-12-22 12:31:02","extension":"png","order_by":6,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":84575,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-7993209/v1/61fb17be961984ea2d954932.png"},{"id":98754801,"identity":"0927b3ec-0131-44ce-9744-e4f93597b721","added_by":"auto","created_at":"2025-12-22 09:25:14","extension":"jpeg","order_by":7,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":137757,"visible":true,"origin":"","legend":"","description":"","filename":"groupimage1.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-7993209/v1/22986e47b439b64a32483d0d.jpeg"},{"id":98778982,"identity":"1f679293-8ce6-46f6-88f6-335de0d04876","added_by":"auto","created_at":"2025-12-22 12:29:52","extension":"png","order_by":8,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":19491,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-7993209/v1/b8d5604c73ad480b976626a9.png"},{"id":98778621,"identity":"402cbbcf-0f56-4692-ae7e-5929947ac0e6","added_by":"auto","created_at":"2025-12-22 12:29:28","extension":"png","order_by":9,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":935,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-7993209/v1/e4fc3db45df04d66809d66ed.png"},{"id":98754803,"identity":"5efae1e8-9adc-4b6f-97a6-658ce2eb2ce7","added_by":"auto","created_at":"2025-12-22 09:25:14","extension":"png","order_by":10,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":19491,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-7993209/v1/1fd05ab84ad775e9b1301bc7.png"},{"id":98754800,"identity":"23a79551-1cfc-429a-a9d2-07606b338a62","added_by":"auto","created_at":"2025-12-22 09:25:14","extension":"png","order_by":11,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":59928,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinegroupimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-7993209/v1/e96f8f02f35ebc5444fa8eae.png"},{"id":98754809,"identity":"5caf4258-aec3-4b0c-9ea5-f2ff3047cf0d","added_by":"auto","created_at":"2025-12-22 09:25:15","extension":"xml","order_by":12,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":191650,"visible":true,"origin":"","legend":"","description":"","filename":"c53685b876a4468e81e3e102eb1d6a5f1structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-7993209/v1/1a533321c7a23154e5548013.xml"},{"id":98754810,"identity":"36e4b85e-62c7-40ab-8bfc-fe9cd60db20b","added_by":"auto","created_at":"2025-12-22 09:25:15","extension":"html","order_by":13,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":205582,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-7993209/v1/1cc30c2845f5e5df5cdaa0a3.html"},{"id":98754804,"identity":"5453e92f-dbfe-47e7-a16c-6b271953d658","added_by":"auto","created_at":"2025-12-22 09:25:15","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":479156,"visible":true,"origin":"","legend":"\u003cp\u003eDepicts the symptoms that were ≥grade 3 and improved overtime. (A) Fatigue (24.6% to 16.2%, \u003cem\u003ep\u003c/em\u003e = 0.03), (B) Abdominal pain (8.7 to 4.2%, \u003cem\u003ep\u003c/em\u003e = 0.03), (C) Anxiety (7.1 to 1.4%, \u003cem\u003ep\u003c/em\u003e = 0.003), (D) Constipation (14.7% to 5.1%, \u003cem\u003ep\u003c/em\u003e = \u0026lt;0.001), (E) Nausea (10.7 to 2.8%, \u003cem\u003ep\u003c/em\u003e = \u0026lt;0.001), (F) Decreased appetite (13.9 to 7.4%, \u003cem\u003ep\u003c/em\u003e = 0.02).\u003c/p\u003e","description":"","filename":"FIG1.png","url":"https://assets-eu.researchsquare.com/files/rs-7993209/v1/8fb056af2154c32060607d09.png"},{"id":98778545,"identity":"fedaf067-ab7b-4df4-bd1d-75ec6f6dbe5b","added_by":"auto","created_at":"2025-12-22 12:29:26","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":111379,"visible":true,"origin":"","legend":"\u003cp\u003eDepicts the symptoms that were ≥grade 3 and worsened overtime. The prevalence of Grade 3 and above neuropathy increased over time (4.0% to 10.2% S4, p = 0.010)\u003c/p\u003e","description":"","filename":"FIG2.png","url":"https://assets-eu.researchsquare.com/files/rs-7993209/v1/de2efa2805f0075c7d7fa5a5.png"},{"id":98783548,"identity":"41b30c9b-bd71-408c-afab-335619bccf66","added_by":"auto","created_at":"2025-12-22 12:42:10","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":2157710,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7993209/v1/2944d3f0-c985-4805-814c-a5ab6e91af49.pdf"},{"id":98754797,"identity":"76bb871c-36cd-4550-8fe1-9e421984534f","added_by":"auto","created_at":"2025-12-22 09:25:14","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":23331,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryTable1.docx","url":"https://assets-eu.researchsquare.com/files/rs-7993209/v1/5d0643e95e9f1ce514039684.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"Symptoms experienced during the first four months of chemotherapy administration: A longitudinal cohort study in an Australian cancer treatment unit","fulltext":[{"header":"Introduction","content":"\u003cp\u003eOver the past decade, cancer therapies have developed significantly, resulting in improved treatment outcomes and extended survival [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Whilst these breakthroughs have given hope to many, patients undergoing chemotherapy continue to experience a high frequency of treatment-related symptoms, impacting their health status, quality of life (QoL), and outcomes [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. The severity of these symptoms varies considerably between patients and throughout their treatment journey [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. Symptoms frequently reported during chemotherapy include physical issues such as pain, fatigue, nausea, and vomiting, alongside psychological concerns such as depression and anxiety [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. Consequently, patients undergoing chemotherapy experience frequent and variable supportive care needs. Managing the physical and psychosocial consequences of systemic anti-cancer therapies is consistently highlighted as an unmet need during survivorship. These unmet needs are associated with reduced QoL, highlighting the need for comprehensive assessment and management of the symptom experience both during and following receipt of cancer therapies [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eResearch on symptom experience and its impact on QoL is growing, but most evidence comes from cross-sectional studies measuring symptoms at a single time point [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. This approach limits insight into symptom trajectories and overlooks the dynamic nature of treatment-related symptoms and evolving supportive care needs [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. Longitudinal evaluation is essential to track symptom changes during treatment and guide assessment tools, interventions, and services that address patients\u0026rsquo; unmet needs [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. Current symptom assessment tools usually assess fewer than 20 symptoms, often underestimating or omitting significant treatment-related issues and leading to unmet supportive care needs.\u003c/p\u003e \u003cp\u003eStudies addressing longitudinal symptom prevalence are often in population subsets, such as those undergoing treatment for breast cancer [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. There is currently limited longitudinal evidence describing the common symptom patterns experienced during chemotherapy administration within a conventional cancer treatment centre. This lack of evidence means that current assessment tools may not adequately reflect the diversity of and changing nature of patient symptom experiences and supportive care needs. Therefore, the aim of this research was to describe the common longitudinal symptom experience in a mixed cohort of patients undergoing chemotherapy in an Australian cancer treatment unit.\u003c/p\u003e"},{"header":"Methods","content":"\u003ch2\u003eStudy design and participants\u003c/h2\u003e\n\u003cp\u003eA prospective, longitudinal, observational cohort study design was used to identify and describe the changes in symptom experiences, levels of distress, and QoL during the first four months of chemotherapy administration. Participants were recruited between December 2017 and January 2020 and comprised adults undergoing chemotherapy at one cancer treatment unit in metropolitan Queensland, Australia. Participants were eligible for inclusion if they met the following criteria: aged 18 years or older; were initiating chemotherapy with curative intent at the hospital and were competent to give informed consent. This study was performed in line with the principles of the Declaration of Helsinki. Ethical approval for this study was sought and obtained by the St Vincent\u0026rsquo;s Health Australia and Aged Care Committee Human Research Ethics Committee (Approval number 16/31, TARGET: Individually tailored health care program for cancer patients).\u003c/p\u003e\n\u003ch2\u003eProcedure\u003c/h2\u003e\n\u003cp\u003eParticipant eligibility was established prior to recruitment through screening the oncology admission records. Eligible participants received a letter inviting them to participate in the study, as well as a consent form and information materials. Patients were enrolled in the study if they completed the associated consent form and returned it to the research team.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eFollowing enrolment, baseline questionnaires were intended to be completed as soon as possible after commencement of their first cycle of treatment and monthly electronic symptom questionnaires for three consecutive months thereafter. Up to two reminder prompts were sent via email and text message to complete the questionnaire. Follow-up phone calls were also made by the research team if a survey was not completed within three days of being administered. These calls checked whether the participant had received the email, and if the study team could assist with its completion. Three attempts at different times of the day were made to contact the participant.\u003c/p\u003e\n\u003ch2\u003eData sources and variables\u003c/h2\u003e\n\u003ch3\u003eDemographic, clinical information, health and lifestyle information\u003c/h3\u003e\n\u003cp\u003eSociodemographic variables were collected at baseline, including age, sex, marital status, education, income ($AUD), family/care responsibilities, ethnicity, living arrangements, and employment. A range of clinical characteristics including cancer type and time since diagnosis were also collected at baseline from patient medical records. Self-reported health and lifestyle information was collected at baseline including height (cm) and weight (kg), smoking status, usual alcohol consumption, engagement in exercise (frequency, intensity), and use of pain medications including both over the counter and prescription products.\u003c/p\u003e\n\u003cp\u003ePresence of comorbid conditions were measured using the Self-administered Comorbidity Questionnaire (SCQ) [9]. The SCQ contains 36 items about occurrence, treatment and functional impact of 12 common comorbid conditions, including cancer [10].\u003c/p\u003e\n\u003cp\u003eThe Malnutrition Screening Tool (MST) was also used at baseline. The MST is a validated brief measure used to assess the risk of malnutrition [11]. The MST asks three questions including whether a person has lost weight without trying and if yes; how much, and whether they have been eating poorly due to decreased appetite [11].\u003c/p\u003e\n\u003ch3\u003eSymptoms Experience\u003c/h3\u003e\n\u003cp\u003eSymptom experience was measured using the National Cancer Institute Patient Reported Outcome Common Terminology Criteria for Adverse Event (PRO-CTCAE). The PRO-CTCAE is validated for reporting treatment side effects in cancer clinical trials [12]. This tool is based on the CTCAE which is commonly used by clinicians to document adverse effects in cancer treatment [13]. Participants self-reported the frequency and severity of adverse events and interference with daily activities in the previous seven days, scoring items on a five-point Likert scale (ranging from 0-4) [12-14]. The PRO-CTCAE was administered at baseline and then monthly for three months thereafter. \u0026nbsp;This was based on the results of a pilot study previously published by the research team [15], which determined that completion of an assessment tool on a weekly basis was too burdensome. Studies indicate that a monthly recall period is not inferior to daily reporting for data reliability [16]. PRO-CTCAE results were interpreted as per the previously published grading algorithm [17].\u003c/p\u003e\n\u003ch3\u003eQuality of Life\u003c/h3\u003e\n\u003cp\u003eQuality of life was assessed using the Assessment of Quality of Life (AQoL-4D) which measures four dimensions of QoL including independent living, relationships, mental health and senses [18]. Participants self-reported 12 items (three items under each sub-scale) using a four-point scale (ranging from 1-4). The AQoL was developed using hospital in-patients with general medical conditions and community members and has demonstrated validity and reliability [19, 20]. Australian norms are available, derived from the Australian national survey of mental health and wellbeing. [21].\u003c/p\u003e\n\u003ch3\u003eDistress\u003c/h3\u003e\n\u003cp\u003eDistress was measured at baseline and follow-up using the Distress Thermometer (DT), which is a brief screening tool that assesses distress levels participants have experienced in the past week. Participants scored a single item on an 11-point scale (ranging from no distress to extreme distress). The DT is sensitive to participants who do not meet anxiety or depression diagnoses [22], and has been validated for use with cancer patients [23].\u0026nbsp;\u003c/p\u003e\n\u003ch2\u003eData analysis\u003c/h2\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eVariable transformation\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eScores on the PRO-CTCAE were transformed using the composite grading algorithm for PRO-CTCAE established by Basch and colleagues [24], which has been assessed for validity, reliability, and sensitivity. The grading algorithm produces a single numerical grading score for adverse events, derived from multiple PRO-CTCAE items. The grading algorithm is scored from 0-3 representing none, mild, moderate and severe symptom experience [24]. Scores on the grading algorithm were further collapsed to a binary variable (yes/no), representing those who did or did not experience adverse events. Participant height (cm) and weight (kg) information was used to generate a Body Mass Index (BMI) score (kg/m\u003csup\u003e2\u003c/sup\u003e).\u003c/p\u003e\n\u003cp\u003eRegarding comorbidities, scores for responses on whether participants had any of the twelve comorbidities listed on the SCQ (excluding cancer), received treatment for them and whether they limited daily activities were tallied to produce an overall SCQ score from 0-36 [10]. Individual scores on the MST questions were combined to create an overall MST score, which categorised participants as low, moderate, or high risk of malnutrition [11].\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003ePresentation of data\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eDescriptive statistics were used to summarise data. Chi-square was used to explore group differences on categorical variables, or Fisher\u0026rsquo;s exact test if expected cell sizes were less than five. Group differences on continuous variables were explored using t-tests, or Mann-Whitney U test if the data were not normally distributed. Repeated measures ANOVA was also undertaken and the Huynh-Feldt correction factor was applied to account for the violation of sphericity, in which observations from the same participant are likely to be correlated [25].\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePRO-CTCAE scores based on the composite grading algorithm were ranked at all timepoints according to the prevalence of the top 20 symptoms experienced. A ranking of one indicated the highest symptom prevalence. This enabled symptoms to be reported as percentage change in prevalence between time points 1 and 4. Similarly, the prevalence of Grade 3 (severe) symptom severity and the percentage change in the prevalence of Grade 3 symptom severity from time 1 to 4 were reported. Missing data were not included in analyses or descriptive summaries. All data analyses were undertaken using SPSS Version 29 [26] and statistical significance was determined at a level of p\u0026lt;0.05.\u003c/p\u003e"},{"header":"Results","content":"\u003ch2\u003eParticipants\u003c/h2\u003e\n\u003cp\u003eOf the 312 eligible patients invited to participate between December 2017 and January 2020, 252 (81%) completed the baseline survey. Reasons for declining to participate included being too sick (n=17), too overwhelmed (n=7), no reason specified (n=31), or other (n=4). Most participants were female (n=164, 65%), of British decent (n=186, 76%), with a mean age of 61\u0026plusmn;12 years. Participant demographics are presented in\u0026nbsp;\u003cstrong\u003eTable 1\u003c/strong\u003e. Approximately 40% of participants had a diagnosis of breast cancer (n=101), 10% had bowel cancer (n=25) and 11% had lung cancer (n=28). Most had been diagnosed within the past year (n=187, 89%), with a mean age at diagnosis of 61\u0026plusmn;12 years. More than half of participants had a family history of cancer (n=142, 57%). More than three-quarters of participants were married or partnered (n=192, 77%) and just under half were employed (n=91, 36.7%). Almost half had an annual household income over $70,000 (AUD) (n=118, 47%).\u003c/p\u003e\n\u003cp\u003eTable\u0026nbsp;1: Participant demographics and clinical characteristics (n=252)\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eDemographic\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eN (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eSex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Male\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e88 (34.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Female\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e164 (65.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eAge (mean, SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e61.0\u0026plusmn;12.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eCancer Diagnosis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Breast Cancer\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e101 (40.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Bowel Cancer\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e25 (10.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Lung Cancer\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e28 (11.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Pancreatic Cancer\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e19 (7.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Oesophageal Cancer\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e18 (7.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Prostate Cancer\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e9 (3.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Lymphoma\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e10 (4.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Ovarian Cancer\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e7 (2.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eOther\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e34 (13.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eAge at cancer diagnosis (mean, SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e60.1\u0026plusmn;12.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eTime since cancer diagnosis \u0026ndash; days (mean, SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e274.0\u0026plusmn;1219.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eTime since cancer diagnosis - years\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;\u0026lt; 1 year\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e187 (89.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;1-2 years\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e14 (6.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;\u0026gt;2 years\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e9 (4.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eFamily history of cancer\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e142 (57.0%)\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e97 (39.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Unknown\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e10 (4.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eMarital status\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Never married/partnered\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e18 (7.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Married/partnered\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e192 (76.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Divorced/separated\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e24 (9.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Widowed\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e16 (6.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eLiving status\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Living with partner and/or others\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e216 (86.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Live alone\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e33 (13.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eEthnicity\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;British/Scottish/Welsh/Irish\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e186 (75.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;European\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e30 (12.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Indigenous Australian\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e1 (0.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Asian\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e2 (0.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Pacific Islander\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e1 (0.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Other\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e25 (10.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eDo you have responsibilities for children at home\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e194 (77.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e56 (22.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eDo you have responsibilities for elders at home\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e244 (97.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e6 (2.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eHighest level of education\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;None\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e1 (0.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Primary\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e4 (1.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Secondary\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e91 (36.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Certificate/Diploma\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e81 (32.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Bachelor/Post-graduate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e73 (29.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eEmployment\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Employed\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e91 (36.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Self-employed\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e27 (10.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Unemployed\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e10 (4.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Retired\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e120 (48.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eHours worked if employed (mean, SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e33.1\u0026plusmn;11.7\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eHours worked if self-employed (mean, SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e28.1\u0026plusmn;15.1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eAnnual household income (AUD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;\u0026lt; $30K\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e32 (13.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;$30-70K\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e80 (34.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;$70-100K\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e37 (16.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;\u0026gt;100K\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e81 (35.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"2\" valign=\"top\" style=\"width: 538px;\"\u003e\n \u003ch2\u003eHealth Characteristics (baseline)\u003c/h2\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eHeight (cm) (mean, SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e168.1\u0026plusmn;9.1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eWeight (kg) (mean, SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e78.6\u0026plusmn;20.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eBody Mass Index (BMI \u0026ndash; kg/m\u003csup\u003e2\u003c/sup\u003e) (mean, SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e27.7\u0026plusmn;6.9\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eSmoking status\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Current\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e10 (4.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Former\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e114 (46.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Never smoked\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e120 (49.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eAlcohol consumption (drinks per week)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;None\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e140 (58.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;1-5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e56 (22.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; 6 or more\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e44 (18.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eAlcohol consumption (daily)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;None\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e67 (28.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;1-2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e76 (31.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;More than 2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e95 (39.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eUse of over-the-counter pain medications (measured at baseline)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e101 (40.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e150 (59.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eUse of strong pain medications (eg. opioids)\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e199 (79.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e51 (20.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eUse of Complementary and Alternative Medicines (CAMs)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e69 (27.6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e181 (72.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eCurrent level of exercise\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;None\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e39 (15.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Limited\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e128 (51.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Regular\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e80 (32.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eUsual exercise intensity\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Low\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e112 (91.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Moderate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e10 (8.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Vigorous\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e1 (0.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eLimited/low intensity exercise\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e43 (35.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eRegular/low intensity exercise\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e68 (55.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eRegular/moderate intensity exercise\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e9 (7.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eUsual exercise frequency (times/week)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e146 (57.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;1-3 times\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e31 (12.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;4 or more times\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e75 (29.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eRisk of Malnutrition (MST)\u003csup\u003e1\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Low\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e139 (66.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Moderate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e28 (13.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;High\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e43 (20.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003eSCQ score\u003csup\u003e2\u003c/sup\u003e at baseline (mean, SD)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e5.1\u0026plusmn;2.8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003ePresence of comorbidities\u003csup\u003e3\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e168 (67.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 406px;\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp;No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 132px;\"\u003e\n \u003cp\u003e70 (28.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cem\u003e\u003csup\u003e1\u0026nbsp;\u003c/sup\u003e\u003c/em\u003e\u003cem\u003eThe Malnutrition Screening Tool (MST) generates a score to define whether a participant is at risk of malnutrition based on if they have lost weight, how much weight has been lost and whether they have experienced decreased appetite\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003e\u003csup\u003e2\u0026nbsp;\u003c/sup\u003e\u003c/em\u003e\u003cem\u003eThe Self-Administered Comorbidity Questionnaire (SCQ) score is a composite measure of 12 comorbidities experienced, if treatment is received and whether the problem causes a limitation to functioning. The maximum score possible is 36.\u0026nbsp;\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003e\u003csup\u003e3\u0026nbsp;\u003c/sup\u003e\u003c/em\u003e\u003cem\u003eConsists of the comorbidities asked in the SCQ, but with the addition of a free text question to specify any additional comorbidities, and the exclusion of cancer, given all participants have a cancer diagnosis.\u003csup\u003e\u0026nbsp;\u003c/sup\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ch2\u003eClinical characteristics\u003c/h2\u003e\n\u003cp\u003eThe mean Body Mass Index (BMI) of the sample was in the \u0026ldquo;overweight\u0026rdquo; category (27.7\u0026plusmn;6.9). Just under half had never smoked (n=120, 49%) and 58% (n=140) did not consume alcohol on a weekly basis. Almost one-third of participants engaged in regular exercise (n=80, 32%, \u0026gt; four times per week) Approximately one in three (n=71, 24%) were at risk of malnutrition based on their MST score and three-quarters (n=168, 67%) had additional comorbidities. Mean SCQ score was 5.1 (\u0026plusmn;2.7) out of a possible score of 36 (with higher scores indicating increased comorbid burden).\u003c/p\u003e\n\u003ch2\u003eSymptom Prevalence\u003c/h2\u003e\n\u003cp\u003eThe questionnaires assessed 54 different symptoms. At baseline, the average number of symptoms experienced by participants was 22.5\u0026plusmn;9.0 and the most prevalent symptoms were fatigue (93%), insomnia (80%), pain (72%), sadness (70%), and problems tasting food or drink (68%).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThroughout the study, the number of symptoms experienced reduced to 21.9\u0026plusmn;9.2 (p=0.002). At the fourth time point, the most prevalent symptoms were fatigue (84%), pain (63%), insomnia (63%), problems tasting food or drink (59%), and aching muscles (59%).\u003c/p\u003e\n\u003ch3\u003eTop three symptoms overall\u003c/h3\u003e\n\u003cp\u003eOf the 54 symptoms assessed, fatigue, pain, and insomnia remained the top three prevalent symptoms present at both baseline and time point 4, affecting 84%, 63% and 63% of participants respectively at the final time point. Of note, there was a significant reduction in the proportions of patients that experienced fatigue (93% to 84%, p=0.005) and insomnia (80% to 63%, p\u003cem\u003e\u0026nbsp;\u003c/em\u003e= \u0026lt;.001), although the proportion of people with these symptoms remained high. The prevalence of pain also reduced from 72% to 63%, but this was not statistically significant (p=0.059) (see Table 2).\u003c/p\u003e\n\u003cp\u003eTable\u0026nbsp;2: Ranking of symptom experience \u0026amp; change in prevalence from Survey 1 to Survey 4. Asterix denote significant difference at * p\u0026lt;0.05, ** p\u0026lt;0.01 and *** p\u0026lt;0.001\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"971\"\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eSymptom\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" valign=\"top\" style=\"width: 206px;\"\u003e\n \u003cp\u003eSurvey 1 n = 252\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" valign=\"top\" style=\"width: 206px;\"\u003e\n \u003cp\u003eSurvey 4 n = 216\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"6\" valign=\"top\" style=\"width: 459px;\"\u003e\n \u003cp\u003eChange from Survey 1 to Survey 4\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003eRank\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003ePrevalence (overall)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003ePrevalence (Grade 3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003eRank\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003ePrevalence (overall)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003ePrevalence (Grade 3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003eRelative change in prevalence (overall)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003eAbsolute change in prevalence (overall)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003eP value\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003eRelative change in prevalence (Grade 3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003eAbsolute change in prevalence (Grade 3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003eP value\u003csup\u003ec\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eFatigue\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e234 (92.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e62 (24.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e182 (84.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e35 (16.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr; 9.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr; 8.6%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.005**\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr; 34.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr; 8.4%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e.030*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eInsomnia\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e202 (80.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e35 (13.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e135 (62.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e21 (9.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr; 22.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr; 17.7%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;.001**\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr; 30.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr; 4.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.199\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003ePain\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e181 (71.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e38 (15.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e137 (63.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e20 (9.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr; 11.7%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr; 8.4%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.059\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr; 38.4%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr; 5.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.067\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eSadness\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e177 (70.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e17 (6.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e117 (54.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e10 (4.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;22.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;16.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;.001**\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;31.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;2.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.427\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eProblems tasting food or drink\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e172 (68.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e33 (13.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e128 (59.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e21 (9.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;13.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;9.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.053\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;26.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;3.4%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.310\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eHeadache\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e166 (65.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e3 (1.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e97 (44.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e2 (0.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;31.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;21.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001**\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;25.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;0.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eConstipation\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e165 (65.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e37 (14.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e99 (45.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e11 (5.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;30.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;19.7%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;.001**\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;65.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;9.6%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;.001**\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eDiarrhea\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e159 (63.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e6 (2.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e117 (54.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e4 (1.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;14.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;8.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.059\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;20.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;0.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.759\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eAnxiety\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e158 (62.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e18 (7.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e119 (55.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e3 (1.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;12.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;7.6%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.109\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;80.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;5.7%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.003**\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eHair loss\u003csup\u003eb\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e150 (59.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e107 (49.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.032*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eDecreased appetite\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e150 (59.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e35 (13.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e109 (50.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e16 (7.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;15.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;9.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.051\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;46.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;6.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.026*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eDry mouth\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e150 (59.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e18 (7.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e97 (44.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e15 (6.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;24.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;14.6%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.002**\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;2.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;0.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eNausea\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e146 (57.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e27 (10.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e95 (44.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e6 (2.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;24.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;13.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.003**\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;73.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;7.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;.001**\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eBloating\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e146 (57.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e15 (6.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e111 (51.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e10 (4.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;11.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;6.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.163\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;23.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;1.4%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.545\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eFrequent urination\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e145 (57.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e100 (46.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.016*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eAbdominal pain\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e14\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e144 (57.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e22 (8.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e111 (51.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e8 (3.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;10.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;5.7%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.227\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;57.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;5.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.036*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eConcentration\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e14\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e144 (57.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e14 (5.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e115 (53.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e8 (3.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;6.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;3.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.403\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;33.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;1.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.388\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eAching muscles\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e140 (55.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e18 (7.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e127 (58.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e9 (4.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;5.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;3.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.513\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;40.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;2.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.232\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eSudden urge to urinate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e136 (54.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e20\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e93 (43.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.021*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eDry skin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e134 (53.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e11 (4.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e113 (52.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e7 (3.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;1.7%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;0.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.853\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;27.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;1.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.633\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eMemory\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e130 (51.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e9 (3.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e114 (52.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e5 (2.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;2.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;1.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.853\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;36.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;1.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.588\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eHeartburn\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e129 (51.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e17 (6.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e88 (40.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e7 (3.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;20.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;10.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.026*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;52.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;3.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.096\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eShortness of breath\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e20\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e125 (49.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e16 (6.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e14\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e105 (48.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e11 (5.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;2.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;1.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.853\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;19.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;1.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.692\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eAching joints\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e118 (46.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e13 (5.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e103 (47.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e9 (4.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;1.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;0.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.853\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;19.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;1.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.667\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eDizziness\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e22\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e103 (40.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e13 (5.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e75 (34.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e5 (2.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;15.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;6.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.182\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;55.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;2.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.148\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eDecreased sexual interest\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e23\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e96 (38.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e22 (8.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e31\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e59 (27.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e21 (9.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;28.4%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;10.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.014*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;11.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;1.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.750\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eNeuropathy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e23\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e96 (38.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e10 (4.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e128 (59.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e22 (10.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;55.6%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;21.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001**\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;155.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;6.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.010*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eMouth or throat sores\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e24\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e95 (37.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e11 (4.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e52 (24.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e5 (2.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;36.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;13.6%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.002**\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;47.7%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;2.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.309\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eBlurry vision\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e92 (36.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e5 (2.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e22\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e86 (39.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e5 (2.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;17.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;6.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.504\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;25.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;0.03%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eItchy skin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e26\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e91 (36.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e5 (2.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e23\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e85 (39.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e3 (1.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;9.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;3.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.503\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;30.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;0.6%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.731\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eCough\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e26\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e91 (36.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e7 (2.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e69 (31.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e4 (1.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;11.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;4.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.379\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;32.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;0.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.557\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eDepression\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e88 (34.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e12 (4.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e29\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e65 (30.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e7 (3.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;13.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;4.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.278\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;33.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;1.6%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.485\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eDifficulty swallowing\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e83 (32.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e11 (4.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e32\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e57 (26.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e5 (2.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;19.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;6.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.130\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;47.7%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;2.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.309\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eUnexpected or excessive sweating\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e29\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e82 (32.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e8 (3.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e68 (31.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e8 (3.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;3.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;1.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.843\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;15.6%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;0.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.803\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eHot flashes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e30\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e77 (30.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e9 (3.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e26\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e70 (32.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e6 (2.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;5.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;1.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.690\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;22.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;0.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.794\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eWatery eyes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e31\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e75 (29.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e7 (2.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e24\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e80 (37.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e7 (3.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;24.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;7.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.115\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;14.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;0.4%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.792\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003ePalpitations\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e32\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e74 (29.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e5 (2.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e36\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e48 (22.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e4 (1.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;24.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;7.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.091\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;5.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;0.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eHoarse voice\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e68 (27.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e5 (2.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e52 (24.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e4 (1.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;10.7%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;2.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.524\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;5.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;0.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eTinnitus\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e65 (25.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e6 (2.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e54 (25.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e5 (2.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;3.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;0.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.915\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;4.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;0.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eShivering or shaking chills\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e35\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e62 (24.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e6 (2.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e39\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e44 (20.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e5 (2.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;17.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;4.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.319\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;4.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;0.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eBody odour\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e36\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e62 (24.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e2 (0.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e42\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e35 (16.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;34.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;8.4%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.030*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;100%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;0.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.502\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eLoss of control of bowel movements\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e37\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e61 (24.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e40\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e43 (19.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;17.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;4.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.316\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eHiccups\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e38\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e58 (23.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e4 (1.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e43\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e33 (15.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e1 (0.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;33.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;7.7%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.036*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;68.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;1.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.380\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eAcne\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e38\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e58 (23.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e1 (0.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e37\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e46 (21.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e5 (2.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;7.4%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;1.7%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.738\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;475%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;1.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.100\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eLoss of control of urine\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e38\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e58 (23.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e29\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e65 (30.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;30.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;7.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.092\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003eNA\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eSwelling\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e39\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e51 (20.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e2 (0.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e30\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e64 (29.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e5 (2.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;46.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;9.4%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.024*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;187.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;1.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.257\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eBreast enlargement or tenderness\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e40\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e45 (17.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e2 (0.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e41 (19.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;6.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;1.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.811\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;100%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;0.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.502\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eCheilitis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e44 (17.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e5 (2.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e38\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e45 (20.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e1 (0.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;18.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;3.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.408\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;75.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;1.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.224\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eWheezing\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e42\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e41 (16.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e1 (0.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e47\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e25 (11.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e1 (0.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;28.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;4.7%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.183\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;25%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;0.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eVomiting\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e43\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e39 (15.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e2 (0.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e46\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e28 (13.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e2 (0.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;16.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;2.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.508\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;12.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;0.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eNosebleed\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e43\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e35 (13.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e35\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e51 (23.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e2 (0.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;69.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;9.7%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.008**\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;200%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;0.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.212\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eDysuria\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e44\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e29 (11.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e5 (2.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e44\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e30 (13.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e3 (1.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;20.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;2.4%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e0.486\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;30.0%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;0.6%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.731\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eHand and foot syndrome\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e45\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e17 (6.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e2 (0.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e45\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e29 (13.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e4 (1.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;100%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;6.7%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.019*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;137.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;1.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e0.421\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003eSkin burns from radiation\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 46px;\"\u003e\n \u003cp\u003e46\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e7 (2.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e1 (0.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 45px;\"\u003e\n \u003cp\u003e48\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e15 (6.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 81px;\"\u003e\n \u003cp\u003e1 (0.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;62.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026darr;11.4%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 75px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.047*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;25%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 80px;\"\u003e\n \u003cp\u003e\u0026uarr;0.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 65px;\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"13\" valign=\"top\" style=\"width: 971px;\"\u003e\n \u003cp\u003e\u003cem\u003eNotes:\u0026nbsp;\u003c/em\u003e\u003cem\u003ePRO-CTCAE scores based on the composite grading algorithm were ranked at Survey 1 and Survey 4 based on the prevalence of symptom experience. A ranking of one indicated the highest symptom prevalence. Given the mean number of symptoms experienced across all timepoints was 22.7 (\u0026plusmn;9.3), we were particularly interested in the change of ranking and prevalence of the top 20 most frequently occurring symptoms and whether they remained, became or were no longer a top 20 symptom between Survey 1 and 4. Symptoms were also reported on with respect to the percentage change in prevalence of symptom experience, that is, the percentage change between percentage prevalence for symptom experience from Survey 1 to 4. Similarly, we also reported on the prevalence of Grade 3 symptom severity (i.e. severe) and the percentage change in prevalence of Grade 3 symptom severity from Survey 1 to 4.\u003c/em\u003e\u003c/p\u003e\n \u003cp\u003e\u003cem\u003e\u003csup\u003ea\u003c/sup\u003e\u003c/em\u003e\u003cem\u003e\u0026nbsp;Comparisons between Survey 1 and Survey 4 were made using\u0026nbsp;\u003c/em\u003e\u003cem\u003ec\u003c/em\u003e\u003cem\u003e\u003csup\u003e2\u003c/sup\u003e\u003c/em\u003e\u003cem\u003etests, including Fisher\u0026rsquo;s exact test, where appropriate.\u003c/em\u003e\u003c/p\u003e\n \u003cp\u003e\u003cem\u003e\u003csup\u003eb\u003c/sup\u003e\u003c/em\u003e\u003cem\u003e\u0026nbsp;The greatest severity for hair loss is Grade 2\u003c/em\u003e\u003c/p\u003e\n \u003cp\u003e\u003cem\u003ec P value for Grade 3 severity compared to all other categories\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003ch2\u003eSymptom Severity\u003c/h2\u003e\n\u003ch3\u003eGrade 3 symptoms\u003c/h3\u003e\n\u003cp\u003eWhilst \u0026gt; 50% of patients experienced more than 20 symptoms at baseline, less than 25% experienced these at a severe (Grade 3) intensity or worse. The Grade 3 or worse intensity symptoms at baseline that affected more than 10% of patients included fatigue (25%), pain (15%), constipation (15%), insomnia (14%), decreased appetite (14%), problems tasting food and drink (14%), and nausea (11%) (See Table 2). There were significant improvements in Grade 3 intensity of fatigue, constipation, anxiety, nausea, decreased appetite, and abdominal pain, however the proportion of patients experiencing Grade 3 intensity peripheral neuropathy increased significantly by the fourth time point (p=0.010) (See Figure 1 and 2).\u0026nbsp;\u003c/p\u003e\n\u003ch2\u003eQuality of life and Distress\u003c/h2\u003e\n\u003cp\u003eOverall QoL improved significantly between time points one and four (p=0.015), as well as the sub-scales of relationships (p \u0026lt;0.001), and senses (p\u003cem\u003e\u0026nbsp;\u003c/em\u003e=0.006). An improvement was also observed for mean distress scores which significantly improved from 3.6\u0026plusmn;2.7 at baseline to 2.7\u0026plusmn;2.7 at the last follow-up (\u003cem\u003ep\u0026nbsp;\u003c/em\u003e\u0026lt; 0.001). These data are presented in Table 3.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003cstrong\u003eTable 3: \u003cem\u003eAssessment of Quality of Life (AQoL) \u0026amp; Symptom Experience\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"99%\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 153px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSurvey 1 (n=252)\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eM\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;(SD)\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eMdn\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;(IQR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSurvey 2 (n=233)\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eM\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;(SD)\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eMdn\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;(IQR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSurvey 3 (n=225)\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eM\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;(SD)\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eMdn\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;(IQR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSurvey 4 (n=216)\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eM\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;(SD)\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eMdn\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;(IQR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eP value\u003csup\u003ea\u003c/sup\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eP value\u003csup\u003eb\u003c/sup\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 153px;\"\u003e\n \u003cp\u003eAQoL\u003csup\u003ec\u003c/sup\u003e overall\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.702 (\u0026plusmn; .214)\u003c/p\u003e\n \u003cp\u003e.713 (.32)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.670 (\u0026plusmn; .235)\u003c/p\u003e\n \u003cp\u003e.705 (.33)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.695 (\u0026plusmn; .219)\u003c/p\u003e\n \u003cp\u003e.723 (.33)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.682 (\u0026plusmn; .226)\u003c/p\u003e\n \u003cp\u003e.706 (.30)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e.015*\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e.028*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 153px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 153px;\"\u003e\n \u003cp\u003eAQoL IL subscale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.859 (\u0026plusmn; .182)\u003c/p\u003e\n \u003cp\u003e.876 (.22)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.849 (\u0026plusmn; .197)\u003c/p\u003e\n \u003cp\u003e.876 (.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.870 (\u0026plusmn; .177)\u003c/p\u003e\n \u003cp\u003e.876 (.17)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.858 (\u0026plusmn; .191)\u003c/p\u003e\n \u003cp\u003e.876 (.22)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.359\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.344\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 153px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 153px;\"\u003e\n \u003cp\u003eAQoL REL subscale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.926 (\u0026plusmn; .110)\u003c/p\u003e\n \u003cp\u003e.969 (.10)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.899 (\u0026plusmn; .132)\u003c/p\u003e\n \u003cp\u003e.899 (.16)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.900 (\u0026plusmn; .126)\u003c/p\u003e\n \u003cp\u003e.899 (.16)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.897 (\u0026plusmn; .130)\u003c/p\u003e\n \u003cp\u003e.899 (.16)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;.001**\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;.001**\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 153px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 153px;\"\u003e\n \u003cp\u003eAQoL SEN scale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.949 (\u0026plusmn; .069)\u003c/p\u003e\n \u003cp\u003e1.00 (.09)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.938 (\u0026plusmn; .079)\u003c/p\u003e\n \u003cp\u003e.941 (.09)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.941 (\u0026plusmn; .068)\u003c/p\u003e\n \u003cp\u003e.941 (.09)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.939 (\u0026plusmn; .071)\u003c/p\u003e\n \u003cp\u003e.941 (.32)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e.006**\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e.033*\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 153px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 153px;\"\u003e\n \u003cp\u003eAQoL MH scale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.887 (\u0026plusmn; .097)\u003c/p\u003e\n \u003cp\u003e.893 (.10)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.881 (\u0026plusmn; .109)\u003c/p\u003e\n \u003cp\u003e.893 (.12)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.891 (\u0026plusmn; .107)\u003c/p\u003e\n \u003cp\u003e.912 (.13)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.887 (\u0026plusmn; .096)\u003c/p\u003e\n \u003cp\u003e.892 (.10)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.564\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.482\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 153px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 153px;\"\u003e\n \u003cp\u003eDistress Thermometer score\u003csup\u003ed\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e3.6 (\u0026plusmn; 2.7)\u003c/p\u003e\n \u003cp\u003e3.0 (5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e2.8 (\u0026plusmn; 2.5)\u003c/p\u003e\n \u003cp\u003e2.0 (5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e2.6 (\u0026plusmn; 2.4)\u003c/p\u003e\n \u003cp\u003e2.0 (4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e2.7 (\u0026plusmn; 2.7)\u003c/p\u003e\n \u003cp\u003e2.0 (4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;.001**\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;.001**\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 153px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 153px;\"\u003e\n \u003cp\u003eNumber of symptoms experienced\u003csup\u003ee\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e22.5 (\u0026plusmn; 9.0)\u003c/p\u003e\n \u003cp\u003e22.0 (13)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e23.6 (\u0026plusmn;9.2)\u003c/p\u003e\n \u003cp\u003e24.0 (13.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e22.7 (\u0026plusmn; 9.6)\u003c/p\u003e\n \u003cp\u003e24.0 (14.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e21.9 (\u0026plusmn; 9.2)\u003c/p\u003e\n \u003cp\u003e22.0 (13.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e.223\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 129px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.002**\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"7\" valign=\"top\" style=\"width: 926px;\"\u003e\n \u003cp\u003eAbbreviations: AQoL \u0026ndash; Assessment of Quality of Life; IL \u0026ndash; Independent Living; REL \u0026ndash; Relationships; SEN \u0026ndash; Sensory; MH \u0026ndash; Mental Health; M \u0026ndash; Mean; Mdn \u0026ndash; Median; SD \u0026ndash; Standard Deviation; IQR \u0026ndash; Interquartile Range\u003c/p\u003e\n \u003cp\u003e\u003cem\u003eNotes:\u003c/em\u003e\u003c/p\u003e\n \u003cp\u003e\u003cem\u003e\u003csup\u003ea\u0026nbsp;\u003c/sup\u003e\u003c/em\u003e\u003cem\u003eComparisons between Survey 1 and Survey 4 were conducted using\u0026nbsp;\u003c/em\u003e\u003cem\u003epaired samples test, with * p\u0026lt;0.05, ** p\u0026lt;0.01, *** p\u0026lt;0.001\u003c/em\u003e\u003c/p\u003e\n \u003cp\u003e\u003cem\u003e\u003csup\u003eb\u0026nbsp;\u003c/sup\u003e\u003c/em\u003e\u003cem\u003eComparisons across Surveys 1 to 4 were conducted using ANOVA repeated measures applying Huynh-Feldt correction factor, with * p\u0026lt;0.05, ** p\u0026lt;0.01, *** p\u0026lt;0.001\u003c/em\u003e\u003c/p\u003e\n \u003cp\u003e\u003cem\u003e\u003csup\u003ec\u003c/sup\u003e\u003c/em\u003e\u003cem\u003eThe Assessment of Quality of Life (AQoL) measure consists of an overall score with minimum and maximum possible scores of 12 and 48 respectively. Lower scores represent better quality of life than higher scores. The tool contains four subscales to measure the domains of Independent Living (IL), Relationships (REL), Sensory (SEN), and Mental Health (MH). Each subscale has a minimum and maximum possible score of zero and 12 respectively. Utility scoring has been applied as per\u0026nbsp;\u003c/em\u003e\u003cem\u003ehttp://www.aqol.com.au/index.php/norms\u003c/em\u003e\u003cem\u003e\u003csup\u003ed\u0026nbsp;\u003c/sup\u003e\u003c/em\u003e\u003cem\u003eThe Distress Thermometer score measures how much distress is experienced over a seven-day period. The minimum and maximum possible scores are zero and ten respectively.\u003c/em\u003e\u003c/p\u003e\n \u003cp\u003e\u003cem\u003e\u003csup\u003ee\u0026nbsp;\u003c/sup\u003e\u003c/em\u003e\u003cem\u003eThe total number of symptoms experienced, regardless of level of severity or frequency and not including sex-specific variables. The maximum possible number of symptoms experienced is 54.\u003c/em\u003e\u003c/p\u003e\n \u003cp\u003e\u003cem\u003e\u0026nbsp;\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cbr\u003e\u0026nbsp;\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eThis prospective, longitudinal cohort study demonstrates the critical need to understand the dynamic and changing symptoms experienced during treatment. The longitudinal data provides novel insights into symptoms experienced during the first four months of chemotherapy, many of which are seldom assessed in current assessment tools [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e]. To our knowledge, this is the first study that reports on the PRO-CTCAE outcomes using the composite grading algorithm in a non-clinical trial setting. Findings revealed a substantial symptom burden, with a mean prevalence of 22.5 of the 54 screened symptoms. The most common symptoms during the first four months of chemotherapy were fatigue, insomnia, pain, sadness, and taste problems. Although the overall symptom burden decreased, the average number of symptoms remained high at 21.9 by the fourth timepoint. This is an important because current instruments often report a narrow set of symptoms [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e]. Conversely, more comprehensive assessment tools often evaluate multiple dimensions experienced in individual symptoms or tumour streams [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e, \u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e]. This demonstrates that current tools may underestimate or omit important symptoms, leading to incomplete clinical pictures, suboptimal patient care, and reduced patient outcomes [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eFindings demonstrated that overall QoL and distress scores significantly improved between timepoints one and four. This improvement in QoL and distress scores persisted despite the relatively high burden of symptoms experienced across the study period. The clinical relevance of the improvement in distress thermometer scores is unclear, as the mean scores at all time points were below the clinically actionable level of 4 [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e], however there was a statistically significant reduction from timepoint one to timepoint four. These improvements over time are supported by the wider literature which suggests that with effective supportive care interventions it is possible for QoL and distress to improve despite the presence of symptoms [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e, \u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]. Further studies should explore the role of comprehensive supportive care and symptom management to address QoL and distress during chemotherapy administration.\u003c/p\u003e \u003cp\u003eConsistent with previous research, we identified the persistence of fatigue, pain, and insomnia as the three most frequently reported symptoms throughout the first four-months of chemotherapy administration [\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e, \u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e]. Despite a statistically significant reduction in their prevalence over the timepoints, these symptoms remained highly prevalent and were among the four most common Grade 3 (severe) symptoms experienced, alongside constipation. These findings demonstrate the chronic nature of fatigue, pain, and insomnia during chemotherapy, as well as the tendency of these symptoms to manifest at severe levels and impacting QoL [\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e]. Importantly, certain populations may be at higher risk of developing symptoms, such as elevated fatigue in postmenopausal women and those undergoing hormonal changes [\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e]. Pain has been shown to be experienced at higher rates amongst those experiencing psychological distress [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e]. This highlights the need for a comprehensive, patient-centred approach to symptom management, which integrates both physical and psychological symptoms and their impacts to patient QoL [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e]. Furthermore, early assessment of these symptoms could enable early supportive care interventions [\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eMost symptoms reduced over the study, however, chemotherapy-induced peripheral neuropathy (CIPN) worsened, with a 55.6% relative increase in prevalence (21.2% absolute change) by the fourth timepoint. This is concerning due to the long-term health effects associated CIPN such as ongoing pain, sensory loss, reduced dexterity, and gait disturbances [\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e]. These effects predispose patients to higher risk of injury and falls as well as worsening QoL and daily functioning [\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e, \u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e]. There are currently limited treatment options for CIPN, suggesting a critical need for the early integration of supportive care strategies to optimise function and QoL [\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eImportantly, we identified a high symptom burden of non-specific symptoms such as aching muscles, reduced concentration, hiccups, and dry mouth. Literature indicates that vague, non-life-threatening symptoms are often deprioritised in clinical care despite significantly impacting QoL [\u003cspan additionalcitationids=\"CR42 CR43\" citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e]. During treatment, clinicians often prioritise monitoring and managing potentially life-threatening side effects or those that could necessitate treatment discontinuation. Despite inadequate assessment of these symptoms, many can be improved with relatively simple lifestyle or supportive care strategies, such as regular exercise [\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e]. Collectively, this suggests a need for comprehensive assessment to identify and respond to non-specific symptoms.\u003c/p\u003e \u003cp\u003eThere are several limitations to consider in interpreting the results of this study. Firstly, participants included in this study were all undergoing chemotherapy at one private hospital. While a diverse range of cancer diagnoses and treatments were included, some symptoms may have been a manifestation of their diagnosis not their treatment. Secondly, people attending a private cancer center are typically of higher socio-economic status, suggesting that they may have greater access to supportive care services and social support [\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e]. Therefore, these results may not be reflective of the symptom experience of populations attending a public cancer service. As the purpose of this study was to represent the needs of a typical population of patients presenting for cancer treatment at a metropolitan hospital, the diversity of the sample included in this study enables a description of the types of needs and experiences that are common in a standard treatment setting on a day-to-day basis. Moreover, the data reported in this study are reflective of only the first four months of receiving systemic cancer treatment. While this longitudinal study is novel in terms of its follow-up of patients over a four-month period, the conclusions drawn are limited to this time period. Continued symptom monitoring for the time following treatment completion may shed further light on the time course of symptom experiences and how best to care for patients following completion of first line treatment. Further, we have not made any adjustment for the number of chemotherapy sessions a patient has had, nor the type of chemotherapy, as this may influence the type and severity of presenting symptoms (for example, the well-established relationship between peripheral neuropathy and platinum- or taxane-based chemotherapy [\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e]). Such factors are critical to explaining why some patients are more likely to experience higher levels of symptoms than others and provide further data that is needed to inform targeted interventions. [\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e]).\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eThis novel research has produced valuable longitudinal insights into the common and most burdensome symptoms experienced by patients attending a metropolitan cancer setting during the first four months of chemotherapy administration. Collectively these findings highlight the need for more robust assessment tools that are utilised early in patients\u0026rsquo; treatment journey and used to inform referral management of treatment-related side effects. While there may be barriers to implementation of routine patient reported measures into routine oncology care, the findings of this study provide evidence which supports the benefits of comprehensive assessment of patients to ensure optimal patient outcomes are achieved [\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e].[\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e] The findings of this study suggest that addressing a broader spectrum of patient-reported symptoms during cancer treatment, including those often overlooked, can provide important data to enhance quality of care and improve patient outcomes.\u003c/p\u003e \u003cdiv id=\"Sec23\" class=\"Section2\"\u003e \u003ch2\u003eImplications for Practice\u003c/h2\u003e \u003cp\u003eThese findings underscore the importance of implementing robust assessment tools early in the patient care pathway to guide referral and management of treatment-related side effects. There is a clear need to expand symptom assessment beyond current assessment tools to enable tailored, comprehensive symptom management and optimise patient outcomes.\u003c/p\u003e \u003c/div\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAuthor Contributions:\u003c/strong\u003e Study conceptualisation, data curation, formal analysis, funding acquisition, investigation and methodology KA, PY, SL, MC, RA, LD, EH, HH, EP, NB, MB, PI. Formal analysis, data visualisation, writing (original draft) KA, TO, BS, MF. All authors reviewed the final manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003cstrong\u003e: \u003c/strong\u003eThis work was supported through Queensland University of Technology and St Vincent\u0026rsquo;s Private Hospital Northside. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDisclosures and Acknowledgements:\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors have no relevant financial or non-financial interests to disclose. The research team would like to acknowledge the contributions of Ms Jennifer Barralet in the establishment of this project. We would also like to acknowledge the support of Queensland University of Technology, Faculty of Health, St Vincent\u0026rsquo;s Private Hospital Northside, and all hospital staff and patients who supported this project.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData Availability\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003e\u003cem\u003eCancer\u003c/em\u003e. 2024 [cited 2025; Available from: https://www.aihw.gov.au/reports/australias-health/cancer.\u003c/li\u003e\n\u003cli\u003eMonnery, D., et al., \u003cem\u003eMulti-professional-delivered enhanced supportive care improves quality of life for patients with incurable cancer.\u003c/em\u003e Int J Palliat Nurs, 2018. \u003cstrong\u003e24\u003c/strong\u003e(10): p. 510-514.\u003c/li\u003e\n\u003cli\u003eBasch, E., et al., \u003cem\u003eOverall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment.\u003c/em\u003e JAMA, 2017. \u003cstrong\u003e318\u003c/strong\u003e(2): p. 197-198.\u003c/li\u003e\n\u003cli\u003ePerez-Alfonso, K.E. and V. Sanchez-Martinez, \u003cem\u003eElectronic Patient-Reported Outcome Measures Evaluating Cancer Symptoms: A Systematic Review.\u003c/em\u003e Semin Oncol Nurs, 2021. \u003cstrong\u003e37\u003c/strong\u003e(2): p. 151145.\u003c/li\u003e\n\u003cli\u003eHsu, M.L., et al., \u003cem\u003eUnmet Needs, Quality of Life, and Financial Toxicity Among Survivors of Lung Cancer.\u003c/em\u003e JAMA Netw Open, 2024. \u003cstrong\u003e7\u003c/strong\u003e(4): p. e246872.\u003c/li\u003e\n\u003cli\u003eEsther Kim, J.E., et al., \u003cem\u003eA review of the prevalence and impact of multiple symptoms in oncology patients.\u003c/em\u003e J Pain Symptom Manage, 2009. \u003cstrong\u003e37\u003c/strong\u003e(4): p. 715-36.\u003c/li\u003e\n\u003cli\u003eThomas, B.C., et al., \u003cem\u003eA longitudinal analysis of symptom clusters in cancer patients and their sociodemographic predictors.\u003c/em\u003e J Pain Symptom Manage, 2014. \u003cstrong\u003e47\u003c/strong\u003e(3): p. 566-78.\u003c/li\u003e\n\u003cli\u003eHo, S.Y., et al., \u003cem\u003eA longitudinal study of depression, fatigue, and sleep disturbances as a symptom cluster in women with breast cancer.\u003c/em\u003e J Pain Symptom Manage, 2015. \u003cstrong\u003e49\u003c/strong\u003e(4): p. 707-15.\u003c/li\u003e\n\u003cli\u003eSangha, O., et al., \u003cem\u003eThe self-administered comorbidity questionnaire: A new method to assess comorbidity for clinical and health services research.\u003c/em\u003e Arthritis Care and Research, 2003. \u003cstrong\u003e49\u003c/strong\u003e(2): p. 156-163.\u003c/li\u003e\n\u003cli\u003eSangha, O., et al., \u003cem\u003eThe self‐administered comorbidity questionnaire: a new method to assess comorbidity for clinical and health services research.\u003c/em\u003e Arthritis Care \u0026amp; Research, 2003. \u003cstrong\u003e49\u003c/strong\u003e(2): p. 156-163.\u003c/li\u003e\n\u003cli\u003eFerguson, M., et al., \u003cem\u003eDevelopment of a valid and reliable malnutrition screening tool for adult acute hospital patients.\u003c/em\u003e Nutrition (Burbank, Los Angeles County, Calif.), 1999. \u003cstrong\u003e15\u003c/strong\u003e(6): p. 458-464.\u003c/li\u003e\n\u003cli\u003eNational Cancer Institute. \u003cem\u003ePatient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE\u0026trade;)\u003c/em\u003e. 2016 [cited 2016 10 October]; Available from: https://healthcaredelivery.cancer.gov/pro-ctcae/.\u003c/li\u003e\n\u003cli\u003eBasch, E., et al., \u003cem\u003eDevelopment of the National Cancer Institute\u0026apos;s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).\u003c/em\u003e Journal of the National Cancer Institute, 2014. \u003cstrong\u003e106\u003c/strong\u003e(9): p. 1-11.\u003c/li\u003e\n\u003cli\u003eKluetz, P.G., et al., \u003cem\u003ePatient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute\u0026apos;s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).\u003c/em\u003e American Society of Clinical Oncology educational book, 2016. \u003cstrong\u003e35\u003c/strong\u003e: p. 67-73.\u003c/li\u003e\n\u003cli\u003ePhung, T.H., et al., \u003cem\u003eUnleashing patient voices: empowering adverse event assessment with complete patient-reported outcomes.\u003c/em\u003e Oncologist, 2024. \u003cstrong\u003e29\u003c/strong\u003e(7): p. e953-e956.\u003c/li\u003e\n\u003cli\u003eMendoza, T.R., et al., \u003cem\u003eEvaluation of different recall periods for the US National Cancer Institute\u0026apos;s PRO-CTCAE.\u003c/em\u003e Clin Trials, 2017. \u003cstrong\u003e14\u003c/strong\u003e(3): p. 255-263.\u003c/li\u003e\n\u003cli\u003eBasch, E., et al., \u003cem\u003eComposite grading algorithm for the National Cancer Institute\u0026apos;s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).\u003c/em\u003e Clin Trials, 2021. \u003cstrong\u003e18\u003c/strong\u003e(1): p. 104-114.\u003c/li\u003e\n\u003cli\u003e\u003cem\u003eAssessment of Quality of Life\u003c/em\u003e. 2016 [cited 2016 31 October]; Available from: http://www.aqol.com.au/index.php/aqolinstruments.\u003c/li\u003e\n\u003cli\u003eHawthorne, G., J. Richardson, and N.A. Day, \u003cem\u003eA comparison of the Assessment of Quality of Life (AQoL) with four other generic utility instruments.\u003c/em\u003e Annals of Medicine, 2001. \u003cstrong\u003e33\u003c/strong\u003e(5): p. 358-70.\u003c/li\u003e\n\u003cli\u003eHawthorne, G., J. Richardson, and R. Osborne, \u003cem\u003eThe Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health-related quality of life.\u003c/em\u003e Quality of Life Research, 1999. \u003cstrong\u003e8\u003c/strong\u003e(3): p. 209-24.\u003c/li\u003e\n\u003cli\u003eHawthorne, G., S. Korn, and J. Richardson, \u003cem\u003ePopulation norms for the AQoL derived from the 2007 Australian National Survey of Mental Health and Wellbeing.\u003c/em\u003e Australian and New Zealand Journal of Public Health, 2013. \u003cstrong\u003e37\u003c/strong\u003e(1): p. 7-16.\u003c/li\u003e\n\u003cli\u003eJacobsen, P.B., et al., \u003cem\u003eScreening for psychologic distress in ambulatory cancer patients.\u003c/em\u003e Cancer, 2005. \u003cstrong\u003e103\u003c/strong\u003e(7): p. 1494-502.\u003c/li\u003e\n\u003cli\u003eGoebel, S. and H.M. Mehdorn, \u003cem\u003eMeasurement of psychological distress in patients with intracranial tumours: the NCCN distress thermometer.\u003c/em\u003e Journal of Neuro-Oncology, 2011. \u003cstrong\u003e104\u003c/strong\u003e(1): p. 357-64.\u003c/li\u003e\n\u003cli\u003eBasch, E., et al., \u003cem\u003eComposite grading algorithm for the National Cancer Institute\u0026rsquo;s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).\u003c/em\u003e Clinical trials (London, England), 2021. \u003cstrong\u003e18\u003c/strong\u003e(1): p. 104-114.\u003c/li\u003e\n\u003cli\u003eHuynh, H. and L.S. Feldt, \u003cem\u003eEstimation of the Box Correction for Degrees of Freedom from Sample Data in Randomized Block and Split-Plot Designs.\u003c/em\u003e Journal of Educational Statistics, 1976. \u003cstrong\u003e1\u003c/strong\u003e(1).\u003c/li\u003e\n\u003cli\u003e\u003cem\u003eIBM SPSS software\u003c/em\u003e. 2024; Available from: https://www.ibm.com/spss.\u003c/li\u003e\n\u003cli\u003eDeshields, T.L., et al., \u003cem\u003eThe persistence of symptom burden: symptom experience and quality of life of cancer patients across one year.\u003c/em\u003e Support Care Cancer, 2014. \u003cstrong\u003e22\u003c/strong\u003e(4): p. 1089-96.\u003c/li\u003e\n\u003cli\u003eLavdaniti, M., \u003cem\u003eAssessment of Symptoms in Cancer Patients Undergoing Chemotherapy in Northern Greece.\u003c/em\u003e Mater Sociomed, 2015. \u003cstrong\u003e27\u003c/strong\u003e(4): p. 255-8.\u003c/li\u003e\n\u003cli\u003eAl Qadire, M., et al., \u003cem\u003eIdentifying Symptom Clusters in Cancer Patients Receiving Chemotherapy using Symptom Occurrence and Distress Dimensions.\u003c/em\u003e Clin Nurs Res, 2023. \u003cstrong\u003e32\u003c/strong\u003e(1): p. 185-196.\u003c/li\u003e\n\u003cli\u003eCutillo, A., et al., \u003cem\u003eThe Distress Thermometer: Cutoff Points and Clinical Use.\u003c/em\u003e Oncol Nurs Forum, 2017. \u003cstrong\u003e44\u003c/strong\u003e(3): p. 329-336.\u003c/li\u003e\n\u003cli\u003eNguyen, L.B., et al., \u003cem\u003eImpact of interventions on the quality of life of cancer patients: a systematic review and meta-analysis of longitudinal research.\u003c/em\u003e Health Qual Life Outcomes, 2023. \u003cstrong\u003e21\u003c/strong\u003e(1): p. 112.\u003c/li\u003e\n\u003cli\u003eLiu, X., et al., \u003cem\u003eThe impact of cognitive behavioral therapy on disease uncertainty, stressful life events, quality of life, anxiety, and depression in glioma patients undergoing chemotherapy: a quasi-experimental study.\u003c/em\u003e BMC Psychiatry, 2025. \u003cstrong\u003e25\u003c/strong\u003e(1): p. 272.\u003c/li\u003e\n\u003cli\u003eSasaki, H., et al., \u003cem\u003ePatient perceptions of symptoms and concerns during cancer chemotherapy: \u0026apos;affects my family\u0026apos; is the most important.\u003c/em\u003e Int J Clin Oncol, 2017. \u003cstrong\u003e22\u003c/strong\u003e(4): p. 793-800.\u003c/li\u003e\n\u003cli\u003eMolassiotis, A., et al., \u003cem\u003eMapping unmet supportive care needs, quality-of-life perceptions and current symptoms in cancer survivors across the Asia-Pacific region: results from the International STEP Study.\u003c/em\u003e Ann Oncol, 2017. \u003cstrong\u003e28\u003c/strong\u003e(10): p. 2552-2558.\u003c/li\u003e\n\u003cli\u003eOh, P.J. and J.R. Cho, \u003cem\u003eChanges in Fatigue, Psychological Distress, and Quality of Life After Chemotherapy in Women with Breast Cancer: A Prospective Study.\u003c/em\u003e Cancer Nurs, 2020. \u003cstrong\u003e43\u003c/strong\u003e(1): p. E54-E60.\u003c/li\u003e\n\u003cli\u003eHickey, M., et al., \u003cem\u003eManaging menopause after cancer.\u003c/em\u003e Lancet, 2024. \u003cstrong\u003e403\u003c/strong\u003e(10430): p. 984-996.\u003c/li\u003e\n\u003cli\u003eMehndiratta, S., et al., \u003cem\u003eA review based study on emotional distress and physical pain in oral and head and neck cancer patients pre- and post-chemotherapy.\u003c/em\u003e Oral Oncology Reports, 2024. \u003cstrong\u003e11\u003c/strong\u003e: p. 100637.\u003c/li\u003e\n\u003cli\u003eCormie, P., et al., \u003cem\u003eThe Impact of Exercise on Cancer Mortality, Recurrence, and Treatment-Related Adverse Effects.\u003c/em\u003e Epidemiol Rev, 2017. \u003cstrong\u003e39\u003c/strong\u003e(1): p. 71-92.\u003c/li\u003e\n\u003cli\u003eBao, T., et al., \u003cem\u003eHealth-Related Quality of Life in Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Clinical Trial.\u003c/em\u003e Oncologist, 2021. \u003cstrong\u003e26\u003c/strong\u003e(11): p. e2070-e2078.\u003c/li\u003e\n\u003cli\u003eTofthagen, C., J. Overcash, and K. Kip, \u003cem\u003eFalls in persons with chemotherapy-induced peripheral neuropathy.\u003c/em\u003e Support Care Cancer, 2012. \u003cstrong\u003e20\u003c/strong\u003e(3): p. 583-9.\u003c/li\u003e\n\u003cli\u003eSchlatter, M.C. and L.D. Cameron, \u003cem\u003eEmotional suppression tendencies as predictors of symptoms, mood, and coping appraisals during AC chemotherapy for breast cancer treatment.\u003c/em\u003e Ann Behav Med, 2010. \u003cstrong\u003e40\u003c/strong\u003e(1): p. 15-29.\u003c/li\u003e\n\u003cli\u003eJensen, E., et al., \u003cem\u003eThe pathway and characteristics of patients with non-specific symptoms of cancer: a systematic review.\u003c/em\u003e BMC Cancer, 2022. \u003cstrong\u003e22\u003c/strong\u003e(1): p. 574.\u003c/li\u003e\n\u003cli\u003eLee, G.W., et al., \u003cem\u003eTreatment of dexamethasone-induced hiccup in chemotherapy patients by methylprednisolone rotation.\u003c/em\u003e Oncologist, 2013. \u003cstrong\u003e18\u003c/strong\u003e(11): p. 1229-34.\u003c/li\u003e\n\u003cli\u003eAdesoye, T., et al., \u003cem\u003ePatient-reported outcomes in older breast cancer survivors with and without prior chemotherapy treatment.\u003c/em\u003e Cancer Med, 2023. \u003cstrong\u003e12\u003c/strong\u003e(17): p. 17740-17752.\u003c/li\u003e\n\u003cli\u003eRana, R.H., K. Alam, and J. Gow, \u003cem\u003eSelection of private or public hospital care: examining the care-seeking behaviour of patients with private health insurance.\u003c/em\u003e BMC Health Serv Res, 2020. \u003cstrong\u003e20\u003c/strong\u003e(1): p. 380.\u003c/li\u003e\n\u003cli\u003eBrown, T.J., R. Sedhom, and A. Gupta, \u003cem\u003eChemotherapy-Induced Peripheral Neuropathy.\u003c/em\u003e JAMA Oncol, 2019. \u003cstrong\u003e5\u003c/strong\u003e(5): p. 750.\u003c/li\u003e\n\u003cli\u003eRoberts, N.A., et al., \u003cem\u003eWhat is needed by staff to implement PROMs into routine oncology care? A qualitative study with the multi-disciplinary team.\u003c/em\u003e Eur J Cancer Care (Engl), 2019. \u003cstrong\u003e28\u003c/strong\u003e(6): p. e13167.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"supportive-care-in-cancer","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"jscc","sideBox":"Learn more about [Supportive Care in Cancer](https://www.springer.com/journal/520)","snPcode":"520","submissionUrl":"https://submission.nature.com/new-submission/520/3","title":"Supportive Care in Cancer","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"Oncology, Symptom management, Chemotherapy, Cancer Care","lastPublishedDoi":"10.21203/rs.3.rs-7993209/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7993209/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003ePurpose\u003c/h2\u003e \u003cp\u003eIndividuals undergoing chemotherapy experience a range of symptoms that can significantly impact their quality of life and treatment outcomes; the prevalence and severity of which can change across their treatment journey. This study aimed to identify and describe the longitudinal symptom experience during the first four months of chemotherapy administration across a range of cancer diagnoses.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eA prospective longitudinal cohort study was conducted at a cancer centre in Queensland, Australia. Monthly surveys assessed symptoms, distress, and quality of life across four months of chemotherapy.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eA total of 252 participants completed baseline surveys (mean age 61\u0026thinsp;\u0026plusmn;\u0026thinsp;12.3 years; 65% female; 40% breast cancer). Participants reported a mean of 22.5\u0026thinsp;\u0026plusmn;\u0026thinsp;9.0 symptoms at baseline, with a statistically significant reduction in symptoms throughout the study period 21.9\u0026thinsp;\u0026plusmn;\u0026thinsp;9.2 symptoms (p\u0026thinsp;=\u0026thinsp;0.002). Fatigue (93%), insomnia (80%), and pain (72%) were most common at baseline and remained highly prevalent throughout the time period. Severe fatigue (25%), pain (15%), and constipation (15%) reduced over time, while peripheral neuropathy and decreased sexual interest increased.\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eThis study has produced insights into the high number of symptoms experienced during the initial four months of chemotherapy. Given the impact of symptoms on treatment outcomes, there is a critical need for the development of appropriate assessment tools capable of capturing this broad range of patient symptom experiences.\u003c/p\u003e\u003ch2\u003eImplications for Cancer Survivors:\u003c/h2\u003e \u003cp\u003eUnderstanding symptom patterns over time can support early identification of high-risk patients, guide personalised supportive care strategies and optimise treatment tolerance and quality of life during and beyond chemotherapy.\u003c/p\u003e","manuscriptTitle":"Symptoms experienced during the first four months of chemotherapy administration: A longitudinal cohort study in an Australian cancer treatment unit","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-12-22 09:25:09","doi":"10.21203/rs.3.rs-7993209/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2026-04-15T22:50:00+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2026-03-22T18:23:38+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"46319912100910640838444681707452753636","date":"2026-03-02T07:52:00+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-12-12T19:34:26+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-12-12T19:31:51+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-11-20T07:25:11+00:00","index":"","fulltext":""},{"type":"submitted","content":"Supportive Care in Cancer","date":"2025-10-31T00:52:52+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"supportive-care-in-cancer","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"jscc","sideBox":"Learn more about [Supportive Care in Cancer](https://www.springer.com/journal/520)","snPcode":"520","submissionUrl":"https://submission.nature.com/new-submission/520/3","title":"Supportive Care in Cancer","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"2f8f925f-f1e9-4326-bf3a-17c29e459333","owner":[],"postedDate":"December 22nd, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[],"tags":[],"updatedAt":"2026-05-11T20:38:27+00:00","versionOfRecord":[],"versionCreatedAt":"2025-12-22 09:25:09","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-7993209","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7993209","identity":"rs-7993209","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}